Investigations of Diabetic Bone Disease:Literature, Registry, and Clinical Studies by Linde, Jakob Starup
   
 
Aalborg Universitet
Investigations of Diabetic Bone Disease
Linde, Jakob Starup
DOI (link to publication from Publisher):
10.5278/vbn.phd.med.00026
Publication date:
2015
Document Version
Publisher's PDF, also known as Version of record
Link to publication from Aalborg University
Citation for published version (APA):
Linde, J. S. (2015). Investigations of Diabetic Bone Disease: Literature, Registry, and Clinical Studies. Aalborg
Universitetsforlag.  (Ph.d.-serien for Det Sundhedsvidenskabelige Fakultet, Aalborg Universitet). DOI:
10.5278/vbn.phd.med.00026
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            ? Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            ? You may not further distribute the material or use it for any profit-making activity or commercial gain
            ? You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to
the work immediately and investigate your claim.
Downloaded from vbn.aau.dk on: April 30, 2017
JA
K
O
B
 STA
R
U
P LIN
D
E
IN
VESTIG
ATIO
N
S O
F D
IA
B
ETIC
 B
O
N
E D
ISEA
SE
INVESTIGATIONS OF 
DIABETIC BONE DISEASE
LITERATURE, REGISTRY, AND CLINICAL STUDIES
BY
JAKOB STARUP LINDE
DISSERTATION SUBMITTED 2015
INVESTIGATIONS OF DIABETIC BONE 
DISEASE 
LITERATURE, REGISTRY, AND CLINICAL STUDIES 
by 
Jakob Starup Linde 
 
Dissertation submitted August 2015 
 
  
Thesis submitted: August 07th, 2015
PhD supervisor:  Prof. Peter Vestergaard
   Aalborg University
Assistant PhD supervisor: MD, PhD Søren Gregersen
   Aarhus University Hospital
   Prof. Bente Lomholt Langdahl
   Aarhus University Hospital
   Prof. Ellen-Margrethe Hauge
   Aarhus University Hospital
PhD committee:  Associate Prof. Mette Dencker Johansen (chairman)
   Aalborg University
   Professor Beata Anna Lecka-Czernik
   University of Toledo College of Medicine
   Professor, Dr. Med. Moustapha Kassem
   University of Southern Denmark
PhD Series: Faculty of Medicine, Aalborg University
ISSN (online): 2246-1302
ISBN (online): 978-87-7112-340-1
Published by:
Aalborg University Press
Skjernvej 4A, 2nd floor
DK – 9220 Aalborg Ø
Phone: +45 99407140
aauf@forlag.aau.dk
forlag.aau.dk
© Copyright: Jakob Starup Linde
Printed in Denmark by Rosendahls, 2015
3 
 
 
CV 
Jakob Starup Linde was born in 1986 in Ræhr, Denmark. He studied Medicine at 
Aarhus University from 2006 and graduated in June 2012 as MD. Shortly after he 
enrolled as a PhD student at the Faculty of Medicine, Aalborg University September 
2012 and was employed at the Department of Endocrinology and Internal Medicine, 
Aarhus University Hospital. He has authored fifteen scientific publications among 
these eight are as first or shared first authorships and have obtained an H-index of 
six. He is sub investigator in the EU project, CARING, during the PhD period and 
have thus been engaged in research collaboration with institutions in Netherlands, 
Sweden, Norway, and Finland. He is supervisor for research year student Sidse 
Westberg Rasmussen, student help Emilie Frey Bendix, and project supervisor for 
PhD student Stine Aistrup Eriksen. In the PhD period he has undertaken educational 
activities in the areas of endocrinology, neurology, and microbiology as a case 
facilitator for primarily 2
nd
 and 5
th
 semester students in Medicine or Medici students, 
Aalborg University. Furthermore, he is a board member from 2013 and from 2014 
also academic secretary in the Jutland medical society: Jydsk Medicinsk Selskab.  
 
  
5 
 
ENGLISH SUMMARY  
Diabetes mellitus is associated with an increased risk of fracture. The risk of a hip 
fracture is 7 fold increased in patients with type 1 diabetes and 1.4 fold increased in 
patients with type 2 diabetes. These differences in fracture rates are unexplained as 
current fracture predictors underestimate fracture risk in both diabetes types. Thus, 
further understanding of the underlying causes of diabetic bone disease may lead to 
better fracture predictors and preventive measures in patients with diabetes. 
 
The aim of the thesis was to investigate the relationship between bone turnover 
markers and diabetes and to investigate disparities in bone status between patients 
with type 1 and type 2 diabetes.  
 
Two systematic reviews and a meta-analysis were conducted to assess and pool what 
is known about bone turnover markers in diabetes. To examine the effects of glucose 
on bone turnover, a state-of-the-art intervention study was conducted. A clinical 
cross-sectional study was conducted, where both patients with type 1 and type 2 
diabetes are examined by sophisticated bone structural scans and biochemical bone 
turnover markers. A registry-based study utilizing the Danish National Hospital 
Discharge registry was performed to investigate associations between comorbidities, 
pharmaceutical use, and biochemical markers and the risk of fracture in patients with 
type 2 diabetes.  
 
Patients with type 2 diabetes had lower bone turnover markers compared to patients 
with type 1 diabetes and bone mineral density and tissue stiffness were increased in 
patients with type 2 diabetes. The bone turnover markers were inversely associated 
with blood glucose in patients with diabetes and both an oral glucose tolerance test 
and an intravenous test decreased bone resorption markers in healthy men. In the 
registry based study; fracture risk in patients with type 2 diabetes were associated 
with low LDL-cholesterol levels and in the cross-sectional study; sclerostin levels 
were associated with fractures in patients with type 1 diabetes.  
 
In patients with diabetes, bone turnover and bone strength are associated with 
clinically relevant measures such as cholesterols and fluctuate on the basis of blood 
glucose level alterations. Future investigations should apply the advanced techniques 
of continuous glucose monitoring to map the circadian rhythm of bone turnover and 
glucose in patients with diabetes. Furthermore, longitudinal studies are needed to 
confirm whether sclerostin and LDL-cholesterol are fracture predictors. 
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DANSK RESUMÉ 
Diabetes mellitus er forbundet med en øget risiko for knoglebrud. Hoftebrud 
forekommer 7 gange så hyppigt hos type 1 diabetespatienter og 1,4 gange så hyppigt 
hos type 2 diabetespatienter. Den øgede risiko for knoglebrud forklares ikke af 
nuværende prædiktorer, da de undervurderer risikoen i begge diabetes typer. 
Yderligere forståelse af baggrunden for diabetiskknoglesygdom kan føre til bedre 
prædiktorer for knoglebrud og præventiv behandling hos diabetespatienter. 
 
Afhandlingens formål var at undersøge sammenhængen mellem 
knogleomsætningsmarkører og diabetes samt at undersøge, om knoglestatus er 
forskellig mellem patienter med type 1 og type 2 diabetes. 
 
For at vurdere hvad der allerede vides om knogleomsætningsmarkører hos 
diabetespatienter blev der foretaget litteraturgennemgange med kvalitativ analyse 
samt kvantitativ analyse i form af en meta-analyse. Effekten af glukose på 
knogleomsætningsmarkører blev undersøgt ved dels at tilsætte glukose til 
blodprøver samt ved udførelsen af et interventionsstudie. Knogleomsætning og 
knoglestruktur blev undersøgt i et tværsnitsstudie, hvor både type 1 og type 2 
diabetespatienter blev undersøgt med avancerede knoglestrukturelle skanninger og 
biokemiske knogleomsætningsmarkører. Et registerstudie der anvender det danske 
Landspatientregister belyste sammenhængen mellem knoglebrud hos type 2 
diabetespatienter med andre sygdomme, lægemiddelforbrug og biokemi målt i 
forbindelse med behandling og kontrol af diabetes. 
  
Ved undersøgelsen havde type 2 diabetespatienter lavere niveauer af 
knogleomsætningsmarkører sammenlignet med type 1 diabetespatienter, mens både 
knoglemineraltæthed og knoglevævsstivhed var højere blandt type 2 
diabetespatienter. De målte knogleomsætningsmarkører faldt med stigende 
blodsukkerniveauer i diabetespatienterne. Desuden reduceredes niveauet af en af de 
målte knoglenedbrydningsmarkører i raske mænd ved både oralt indtag af glukose 
og infusion af glukose i en blodåre. Registerundersøgelsen viste at knoglebrud i type 
2 diabetespatienter var forbundet med lave niveauer af LDL kolesterol, medens der i 
tværsnitsstudiet var en sammenhæng mellem knogleomsætningsmarkøren sclerostin 
og knoglebrud hos type 1 diabetespatienter. 
 
Hos diabetespatienter findes der sammenhænge mellem knogleomsætning og 
knoglestyrke og vigtige behandlingsmæssige markører som kolesteroltal og 
blodsukkerniveauer. Fremtidige undersøgelser bør anvende kontinuerlig 
glukosemonitorering til at kortlægge døgnrytmen af knogleomsætning og 
blodsukkerniveauer hos diabetespatienter. Desuden er longitudinellestudier 
nødvendige for at bekræfte, om sclerostin og LDL kolesterol er frakturprædiktorer. 
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1. INTRODUCTION 
1.1 DIABETIC BONE DISEASE 
Diabetes and osteoporosis are common diseases both worldwide and in Denmark (1, 
2). Diabetes is associated with morbidity and mortality, but also an increased risk of 
fracture. Patients with diabetes are especially at risk of hip fractures, which may 
cause individual distress but also relates to an increased risk of death. Paradoxically, 
the normally used methods to predict fracture underestimate the fracture risk in 
patients with diabetes. Furthermore, the evidence is sparse whether the bone 
remodeling is altered in patients with diabetes. Thus, the mechanism, prediction, and 
prevention of diabetic bone disease are unrevealed. This study will review the 
current knowledge of diabetic bone disease and add to it by investigating bone 
turnover markers, bone structural scans, and fracture predictors in patients with 
diabetes. 
 
1.2 OSTEOPOROSIS 
Osteoporosis is a highly prevalent disease with an estimated 200 million individuals 
suffering worldwide from it (3, 4). In Denmark close to 500.000 individuals have 
osteoporosis. However, only 130.000 are treated or diagnosed with osteoporosis. 
Thus, missed diagnoses are common (1, 5). The total cost of osteoporotic fractures 
was 1.5 billion EUR in Denmark in 2011 with hip fracture being the most expensive 
fracture type (6). Thus, osteoporotic fractures account for a large part of health 
expenses in Denmark. Until the occurrence of a low energy fracture osteoporosis is 
asymptomatic, this makes preventive measures difficult. Osteoporosis is usually 
associated with aging due to an increased bone resorption compared to bone 
formation, and for women a dramatic loss of bone at the menopause makes them 
more susceptible to osteoporosis (7). The decrease in bone content is related to an 
increased bone resorption, which is not balanced by an equal increase in bone 
formation (7). Diabetes may present a secondary cause of osteoporosis and even 
weak associations between diabetes and osteoporosis will lead to a significant 
number of fractures among the 300.00 patients with diabetes in Denmark. Other 
secondary causes of osteoporosis includes disuse osteoporosis due to 
immobilization, malabsorption or low intake of vitamin D and calcium, bone toxic 
substances as smoking and certain pharmaceuticals as glucocorticoids and 
antiepileptics, and an altered bone turnover as observed in hyperparathyroidism,  
hyperthyroidism, and pituitary diseases. Inflammatory diseases as rheumatoid 
arthritis and inflammatory bowel disease are also associated with osteoporosis, 
which may be due to use of pharmaceuticals (glucocorticoids) and inflammatory 
cytokines (8).  
It is possible to measure the decrease in bone by the bone mineral density (BMD), 
which predicts fracture risk (9). By screening individuals at risk preventive measures 
are thus possible. In certain patient subgroups, as patients with diabetes and patients 
with renal failure, BMD is less useful (10, 11). The age of the general population 
increases, and elderly subjects are more susceptible to fractures (12) which increase 
20 
 
mortality and immobilization (13). Therefore, it is important to take measures to 
prevent osteoporosis and fractures. 
 
1.21 BONE STRUCTURE, CELLS, AND TURNOVER 
Bone consists of mineralized matrix (hydroxyapatite), non-mineralized matrix 
(collagen), and cells (osteoclasts, osteoblasts, and osteocytes). The hydroxyapatite 
crystals provide mechanical resistance and additional strength to the collagen 
structures, whereas the network of collagen, mainly type I collagen, contributes with 
stability and elasticity (14). Bone turnover consists of a combination of bone 
resorption and bone formation as presented in Figure 1 (15-18).  
 
 
Figure 1. Bone remodeling (From Imai et al. permission is not required) (18) . 
 
Osteoclasts are cells which are able to resorp bone and osteoblasts are cells capable 
of forming new bone whereas the function of osteocytes may be regulatory. 
Osteoclasts are multinucleated giant cells differentiated from monocyte/macrophage 
precursor cells and resorb bone under tight regulation (19). Osteoclasts resorb bone 
by adhering to the underlying bone and creating a sealing zone where acidic 
proteases are secreted, which degrade bone (19, 20). The degradation products; 
collagen, calcium, and phosphate are processed within the osteoclast and released to 
the circulation (19). Osteoblasts derive from mesenchymal stem cells and are bone 
forming cells and regulate osteoclast differentiation (21). Osteoblasts regulate 
osteoclasts by secretion of Receptor Activator of Nuclear factor Kappa beta Ligand 
(RANKL) and osteoprotegerin (OPG). During bone formation osteoblasts produce 
collagen type I, other non-collagenous proteins, and insulin-like growth factor-1 
(IGF-1) that recruit additional osteoblasts during formation. Following bone 
resorption, osteoblasts migrate to the resorption area and create non-mineralized 
matrix and regulate the following mineralization (21). Osteocytes are thought to be 
encased osteoblasts in the mineralized bone which becomes less active as they stop 
synthesizing matrix. They may function as sensors of mechanical loading and may 
both regulate bone formation and bone resorption (22) by secretion of sclerostin, 
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OPG, and RANKL and furthermore regulate the phosphate balance by secreting 
fibroblast growth factor-23 (FGF-23) (23). Thus, osteocytes, osteoblasts, and 
osteoclasts communicate through several pathways as presented in Figure 2. These 
pathways are further described below. 
 
 
Figure 2. Overview of the interactions between osteocytes, osteoblasts, and 
osteoclasts. Red arrows are inhibitory actions, green arrows stimulatory actions, 
and blue arrows secreted products. 
  
1.22 REGULATORS OF BONE METABOLISM 
1.221 PTH AND VITAMIND D 
Parathyroid hormone (PTH) and vitamin D are important hormones of bone 
turnover. PTH is produced in the parathyroid glands as a response to low blood 
calcium levels (24). PTH releases calcium to the bloodstream by different 
mechanisms; 1) increasing bone resorption in an osteoclast mediated mechanism 2) 
stimulating the tubular reabsorption of calcium 3) decreasing the reabsorption of 
phosphate in the kidneys, and activating vitamin D from the 25 hydroxy form to 
1,25 dihydroxy D vitamin (1,25 OHD) (24). Vitamin D is produced in the skin by 
exposure to sunlight, but is also a part of the dietary intake through meats, fish, milk, 
and eggs (24). 1,25 OHD increases absorption of calcium from the intestine and 
reabsorption in the kidneys, stimulates differentiation of osteoclasts, and controls 
mineralization in the bone (24). 
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1.222 RANKL/OPG SYSTEM 
RANKL is mainly produced by the osteoblasts and binds to the RANK on 
osteoclastic precursor cells, which promotes differentiation, activation, and survival 
of osteoclasts (25). Both PTH and 1,25 vitamin D increases the production of 
RANKL. OPG is a decoy receptor to RANKL and inhibits the activation of RANK 
(25, 26). The RANK/RANKL/OPG system is illustrated in Figure 3. A RANKL 
antibody is used as pharmacological treatment of osteoporosis and decreases the risk 
of fractures in osteoporotic women (27). Through the interaction with primarily 
osteoclasts the RANKL/OPG system has important effects on bone resorption and is 
a valuable target in osteoporosis treatment. Whether the RANKL/OPG system is 
affected by diabetes is unknown, but it may contribute to the mechanisms of bone 
deterioration. RANKL and OPG have been investigated in patients with diabetes 
compared to controls. Serum (s-) RANKL levels are not different when comparing 
patients with type 1 diabetes (T1D) and patients with type 2 diabetes (T2D) with 
controls (28-30), whereas s-OPG is increased in patients with T1D and T2D 
compared to controls (26, 28-32).  However, one study reports decreased s-OPG in 
young patients with T1D compared to controls (33). My study will address the 
RANK system and bone in diabetes. 
 
 
Figure 3. RANK/RANKL/OPG pathway (From Khosla with permission) (25). 
 
1.223 WNT PATHWAY 
The Wnts are proteins that bind to the low-density lipoprotein receptor related 
proteins 5 and 6 (LRP-5 and LRP-6). Activation of the receptors prevents 
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degradation of β-catenin, which alter gene regulation and stimulates osteoblast 
differentiation, thus the Wnt and LRP-5/LRP-6 signaling is a determinant of bone 
mass (34, 35). Sclerostin is an important antagonist of Wnts by binding to and 
inactivating signaling from LRP-5 and LRP-6 (35). Sclerostin antibodies are tested 
for pharmaceutical use with positive results (36).Wnt may affect glucose 
metabolism and regulate glucagon-like peptide-1 (GLP-1) secretion. LRP-6 
mutations cause hyperlipedemia and diabetes and LRP-5 is essential for glucose 
induced insulin secretion and normal cholesterol in mice (35). The Wnt pathway 
may contribute to both bone health and glycemic regulation in patients with 
diabetes; however few human studies have been conducted. One study reports 
increased s-sclerostin levels in patients with T2D compared to patients with T1D 
(37), however age differences are large between the groups. S-sclerostin levels are 
not different when comparing controls and patients with T1D (37, 38), whereas it is 
increased in patients with T2D (37, 39). My study will touch on the role of 
sclerostin, low density lipoprotein (LDL)-cholesterol, and bone status and fracture 
risk in diabetes. 
 
1.224 FGF-23  
FGF-23 is a phosphatonin mainly secreted from the osteocytes, and the highest 
expression of FGF-23 is in bone. It reduces phosphate levels by limiting 
reabsorption in the renal tubules and inhibiting the renal production of 1,25 OHD 
vitamin. Furthermore, it may regulate PTH. In patients with chronic kidney disease 
FGF-23 levels are elevated, possibly, to preserve normal phosphate levels (40, 41), 
whereas levels may be normal in patients with diabetes (42). Furthermore, FGF-23 
is an inhibitor of bone mineralization the mechanism, however, is not elucidated and 
the effects may be indirect. FGF-23 may be regulated by other systems, as 1,25 
OHD vitamin induces expression of FGF-23 in osteocytes (40, 41). A single study 
evaluated s-FGF-23 in patients with T2D and controls and found no difference, 
however characteristics of the included participants were not reported (42). My 
study will evaluate FGF-23 levels in diabetes and their relationship with bone status. 
 
1.3 DIABETES MELLITUS 
Diabetes mellitus is a highly prevalent disease not only in Denmark with 320.000 
registered patients with diabetes (43), but also worldwide with an estimate of 387 
million suffering from the condition in 2014 (2). This number is increasing towards 
592 million individuals suffering from diabetes in 2035 (2). This is of great concern 
as diabetes mellitus is related to increased morbidity and mortality (44). As with 
osteoporosis, diabetes is a costly disease. In 2012 the US spent 245 billion dollars on 
direct medical costs and reduced productivity (45). In 2006 Denmark spent 4.2 
billion EUR in direct and indirect costs (46). Diabetes mellitus is in general divided 
into two types: T1D and T2D (47). Patients with T1D are defined by a complete 
deficiency of insulin caused by pancreatic β-cell destruction and in many cases it 
may be serological confirmed by the presence of autoantibodies against the 
pancreatic islets (47). The more prevalent T2D is defined by insulin resistance and 
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an inadequate compensatory insulin secretion resulting in a functional insulin 
deficiency and hyperglycemia (47). A common phenotypic trait of patients with 
T2D is obesity, whereas patients with patients with T1D usually are normal weight; 
however not all patients with T2D exhibit this trait. The obesity itself causes insulin 
resistance (47). Due to a remaining production of insulin in patients with T2D they 
may go undiagnosed for several years in which the hyperglycemic conditions may 
affect various tissues (47). Thus, at the time of diagnosis of patients with T2D long 
term complications may be observed (47). Although the diabetes types differ in 
characteristics they are diagnosed by the same criteria. The diagnosis of diabetes is 
based on the measurement of increased glycated hemoglobin A1c (HbA1c) levels, 
increased fasting plasma (p-) glucose levels or increased two hour p-glucose value 
after an oral glucose tolerance test (OGTT) (47).  
 
1.31 DIABETES COMPLICATIONS 
Diabetes is characterized by hyperglycemia, due to insulin resistance and/or reduced 
beta cell function, which causes long term damage to specific organs (47). Long 
term complications to diabetes include microvascular disease; nephropathy, 
neuropathy, and retinopathy, and macrovascular disease; stroke, acute myocardial 
infarction, and peripheral vascular complications (47). Another recently added 
complication to diabetes is fracture (11, 48). Diabetes complications are related to 
advanced glycation end-products (AGE). AGE are compounds formed by non-
enzymatic reactions between sugars and amine residues on lipids, protein, and 
nucleic acids. In patients with diabetes AGE are formed as a result of 
hyperglycemia, oxidative stress, and lipids and accumulate within various organs 
including kidney, retina, and atherosclerotic plaques (49). These AGEs may also 
accumulate in bone and contribute to the diabetic bone disease.  
 
1.4 DIABETES AND FRACTURE 
Recently, research has intensified on the relationship between diabetes and fracture. 
An association is found between an increased risk of fracture and diabetes mellitus 
(11, 48). In a meta-analysis Vestergaard reports a relative risk of hip fracture risk of 
6.94 for patients with T1D and of 1.38 for patients with T2D (11). Further, this 
study reveals a discrepancy between BMD levels and fracture risk. BMD is 
increased in patients with T2D and slightly decreased in patients with T1D, but not 
to the extent that explains the observed fracture risk (11). When patients with T2D 
are stratified by gender the increased fracture risk is still apparent in both genders 
(48). Later studies confirm these findings in patients with T2D (50, 51) and a recent 
study revealed a lifelong increased fracture incidence in patients with T1D (52).  
The Fracture Risk Assessment Tool (FRAX) that uses common risk factors 
including BMD provides 10 year fracture risk estimates (53). When applying FRAX 
to diabetes it underestimates both hip fracture risk and major osteoporotic fracture 
risk in patients with T2D (54) (Figure 4), thus common used fracture predictors 
seem of poor use in diabetes.  
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Figure 4. FRAX prediction of fracture in patients with type 2 diabetes and actual 
fracture rates. The dotted line indicates the line of identity (perfect concordance). 
*p < 0.05, **p < 0.001. (from Giangregorio with permission) (54). 
 
When neither BMD nor other risk factors for osteoporosis are useful predictors, then 
bone turnover markers, innovative bone scanning techniques, and other variables as 
patient characteristics, pharmaceutical treatment, and glycemic status may add to the 
prediction of fractures. Furthermore, it is unknown whether the same factors predict 
fractures in patients with T1D and T2D. 
Using the FRAX model; hip fractures in patients with diabetes compared to non-
diabetes subjects are especially increased in those younger than 60 years with a 
hazard ratio (HR) of 4.67 (55). Although the HR decreased with increasing age the 
risk remained significantly elevated in diabetes patients (55). Another study using 
the FRAX model find that BMD and other risk factors predict fractures in old 
patients with T2D (mean age 73), but suggests using another threshold for BMD in 
patients with T2D, as the fracture risk is increased at a given BMD or FRAX score 
compared to non-diabetes individuals (56). However, the greatest fracture risk 
increase is observed in patients with T2D younger than 60 years old and another 
BMD threshold may not predict fractures in this group. Other yet unknown 
predictors of fracture may be of use in patients with diabetes.  
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A recent study using the Scottish national registry, however, questions previous 
findings as they find a three times elevated fracture risk in patients with T1D and 
only a borderline significant increased risk in women with T2D but not in men with 
T2D (57). Even so, patients with diabetes seem more prone to a fracture, and 
especially a hip fracture, which is related to increased mortality, morbidity (58), and 
socioeconomic costs (59). There is a need for a reliable predictor of fracture in 
patients with diabetes to avoid both suffering for the individual and economical 
costs for the society. 
The increased fracture risk in patients with diabetes may be explained both by 
deficits in bone biochemical competence which is based on the bone structure; bone 
matrix, bone mineral, and the collagen composition and an increased rate of falls. 
Furthermore, falls may be increased due to complications (neuropathy, retinopathy), 
hypoglycemic events, and pharmaceutical treatment such as anti-hypertensive drugs 
(Figure 5). 
 
 
Figure 5. Factors that relate to falls and bone quality and thereby fractures in 
patients with diabetes 
 
1.41 DIABETES, FALLS, AND FRACTURES 
An increased risk of fracture may be multi-factorial and caused by both a decrease 
of bone quality and an increase in risk of falls (60, 61). In diabetes, retinopathy and 
neuropathy may increase the risk of falls due to poor eyesight and decreased 
peripheral sensation. A Danish registry based study finds that patients with diabetes 
with no complications have an increased risk of fracture and that no single diabetes 
related complication could explain the risk (62). Hypoglycemia may also increase 
the risk of fracture (63, 64). A study by Vestergaard et al. finds an increased risk of 
fracture in diabetes after adjustment for hypoglycemic events (65). Further, both the 
studies of Bonds et al., Napoli et al. and Schwartz et al. adjust by self-reported falls 
and still find an increased risk of fractures in patients with diabetes (50, 66, 67). The 
recent study by Lee et al. (68) reports an increased risk of fall-related fractures in 
patients with diabetes. However, falls do not offer a full explanation for the 
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increased risk of fractures and suggests there may be additional underlying 
mechanisms.  
T2D is associated with obesity, and the fat deposits may act as internal hip 
protectors (69). As external hip protectors decrease fracture risk in relation to falls 
(70, 71) this factor may - besides the increased BMD – offer an explanation for the 
decreased fracture risk in patients with T2D compared to patients with T1D. 
Although, falls may explain some but not all of the association between fracture and 
diabetes; fractures still are multi-factorial and rely on – among other factors - 
decreased bone quality. It is unknown if hypoglycemia may affect bone quality. 
  
1.42 DIABETES DURATION 
The duration of diabetes may influence fracture risk. After diagnosis of diabetes a 
rapid lowering of p-glucose levels may increase the risk of falls and thereby 
fractures. A longer duration of diabetes would mean a longer period of elevated p-
glucose and increase the formation of AGE (72). Insulin, which is a bone anabolic 
factor (73), is outside normal range for a prolonged period in diabetes. Decreased 
exposure to insulin and formation of AGE are both factors which may relate to bone 
quality. Thus, the risk of fractures at the time of diabetes diagnosis could be due to 
an increased number of falls, whereas longer diabetes duration may relate to 
decreased bone quality. Patients with T1D have diabetes for the remainder of their 
lives and the fracture risk may be due to decreased bone quality caused by the long 
duration of diabetes. However they are also susceptible to hypoglycemia throughout 
life. Patients with T2D on average have shorter diabetes duration than patients with 
T1D. Hypoglycemia may be rarer than in patients with T1D; however bone quality 
may also be affected as the patients with T2D may have diabetes for years previous 
to diagnosis and a normal longevity (74). 
A recent Spanish study reports an increased risk of fracture in newly diagnosed 
patients with T2D when adjusted for previous falls (75). Other studies report an 
association between increased diabetes duration and fracture risk (76, 77). Although 
these studies are conflicting, they may present the same mechanism as diabetes 
duration in patients with T2D is difficult to assess. The patients with T2D in the 
study by Martinez-Laguna et al. (75) may have had diabetes for a longer period 
previous to diagnosis (78). 
 
1.43 GLUCOSE, HBA1C, AND DECREASED BONE QUALITY 
Insulin resistance and β-cell dysfunction lead to increased p-glucose levels in 
patients with diabetes (47). Increasing glucose levels relate to an increased 
production of AGE (79). Enzymatic cross-linking plays an important role in the 
bone strength. However, by glycation and oxidation these crosslinks can become 
non-enzymatic AGEs (80). AGE crosslinks are less strong and may decrease bone 
quality and thereby bone strength. The mineralization of bone reflected in scanning 
techniques by BMD may be normal, whereas the tissue giving both strength and 
elasticity may be defect. Therefore, the mean glycemic burden (as reflected by 
HbA1c) may play a very important role in the pathogenesis of diabetic osteoporosis. 
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In a retrospective cohort, the risk of hip fracture is reported to be increased with 
HbA1c levels above 9 % compared to levels of 6-7 % (81). Another study report, 
that a 1 % increase in HbA1c level is associated with almost a two times increased 
risk of a prevalent fracture (82). In the same study, a pmol/ml increase of 
pentosidine, an AGE marker, increases the fracture risk by 1.02 (82). Similar results 
have previously been reported for HbA1c (83). However, a randomized controlled 
trial found no difference in falls or fracture between standard glycemic control 
(HbA1c of 7.5 %) and intensive glycemic control (HbA1c of 6.4 %), although the 
total number of fractures were limited (84). 
Results are conflicting regarding the relationship between BMD and HbA1c. Poor 
glycemic control is associated with worse bone outcomes in women with T1D, 
which is reflected by BMD (85). Vestergaard finds no effect of HbA1c on BMD in 
patients with diabetes (11), whereas Ma et al. reports a positive effect of HbA1c on 
BMD at the spine and hip (86). A single HbA1c value may not be informative of the 
general glucose control in patients with diabetes as the values may rapidly improve 
or worse. The relation between yearlong averages of HbA1c and BMD may add to 
the understanding of the bone structure in diabetes. 
 
1.5 DIABETES AND STRUCTURAL BONE SCANS 
Table 1 presents studies that have investigated bone structure in diabetes by different 
scanning techniques. Dual energy x-ray absorptiometry (DXA) scan is used to 
measure BMD and thereby diagnose osteoporosis and predict fracture risk (9, 87). 
BMD is, as described above, increased in patients with T2D and slightly decreased 
in patients with T1D compared to non-diabetes subjects even though both have an 
elevated fracture risk (11). A recent meta-analysis report decreased BMD in patients 
with T1D compared to non-diabetes subjects at the spine and at the hip in women, 
but not in men (88). A further meta-analysis report increased BMD in patients with 
T2D (86). Few studies have examined differences in BMD between patients with 
T1D and T2D. Age and BMI adjusted hip and femoral neck BMD is lower in 
patients with T1D than patients with T2D (89, 90) and in women with T1D than 
women with T2D (91), however others find no difference in BMD (37, 89, 92, 93). 
BMD is as measure of the mineralized tissue and will not detect weakening or 
disorganization of the non-mineralized matrix including collagen, which limits the 
use in diseases involving collagen. Rats with diabetes presented with decreased 
hydroxyapatite crystal perfection and decreased calcium / phosphate ratio compared 
to controls (94), thus mineralization was altered in rats with diabetes with a decrease 
in bone strength which may not be detected by BMD. Furthermore, whether BMD 
differences between patients with T1D and T2D are related to bone turnover is 
unknown (95). BMD seems less useful in diabetes but other techniques may add to 
the diagnosis and fracture risk assessments in subjects with diabetes. Trabecular 
bone score (TBS) may improve the value of traditional BMD measures in DXA. 
TBS is suggested to predict fracture risk better than traditional DXA in women with 
diabetes (96). TBS is lower in the lumbar spine of women with diabetes even though 
BMD is increased compared to controls (97). Another study finds no differences in 
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TBS in women with diabetes at the femur and spine and in men with diabetes at the 
hip compared to controls (98). The TBS values are positively correlated to lower 
HbA1c linking the TBS score directly to diabetes (97, 98). 
High Resolution peripheral Quantitative Computed Tomography (HRpQCT) scan is 
a new technique which creates high resolution images of the bone tissue at 
peripheral sites (tibia, radius) and enables a distinction between cortical and 
trabecular bone (99). In patients with T2D, patients with a fracture had greater 
cortical pore size and cortical porosity at the tibia and radius compared to patients 
without a fracture (100). The same is not observed in non-diabetes individuals (100). 
Basic parameters as volumetric BMD (vBMD) are found not to differ between 
patients with diabetes and non-diabetes subjects (101, 102), even in a population 
where hip BMD is increased (102). Further, cortical porosity and cortical pore size 
are not different between patients with diabetes and controls (100-102). A single 
study recently evaluated HRpQCT in patients with T1D compared to controls (103). 
This study report lower vBMD at the radius and higher total bone area in patients 
with T1D compared to controls (103). Furthermore, it reports that patients with T1D 
and microvascular disease have deficits in the cortical and trabecular 
microarchitecture compared to patients with T1D without microvascular disease 
(103). However, the study sizes are small with 55 individuals at most in each group 
(see Table 1), which may explain the lack of differences (100-103). Larger studies 
are needed to compare differences between patients with T1D and T2D and further 
relate the measures of bone strength and porosity to bone turnover markers and 
markers of bone regulating pathways. My study assesses differences in HRpQCT 
variables between patients with T1D and T2D in a larger material than previous 
reported. Quantitative Computed Tomography (QCT) is another technique that 
visualizes bone at central positions but not with high resolution as the HRpQCT. 
QCT discriminate non-diabetes individuals with a vertebral fracture at a better rate 
than DXA (104) and it is also superior to DXA in discriminating previous hip 
fractures (105). A single study supports these results in patients with diabetes (106), 
however, again the number of individuals in each group is small (n=20). Magnetic 
resonance imaging (MRI) scan can visualize bone. In diabetes, young women with 
T1D display lower bone volume and increased trabecular spacing, which is 
associated with microvascular complications in particular (107).   
 
Reference Design Number of patients Result 
Studies comparing Dual energy x-ray absorptiometry between diabetes and 
non-diabetes subjects 
Dhaliwal et al. 
2014 (97). 
Cross-
sectional. 
57 women with T2D 
and 43 women 
without diabetes. 
Lumbar spine BMD was 
higher and lumbar spine 
TBS lower in women 
with T2D compared to 
controls. TBS was 
associated with 
glycemic control. 
30 
 
Kim et al. 
2015 (98). 
Cross-
sectional. 
1,229 men (325 with 
diabetes) and 1,529  
postmenopausal 
women (370 with 
diabetes). 
Lumbar spine BMD was 
lower in men and 
women with diabetes 
compared to control. 
Lumbar spine TBS was 
lower in men and 
women compared to 
controls.  
Leslie et al. 
2013 (96). 
Retrospective 
cohort. 
29,407 women 50 
years and older 
(2,356 with 
diabetes). 
BMD was higher and 
lumbar spine TBS was 
lower in patients with 
diabetes. TBS was a 
BMD independent 
predictor of fracture in 
patients with diabetes. 
Ma et al. 2012 
(86). 
Meta-analysis. 15 observational 
studies (3,437 
patients with T2D 
and 19,139 controls). 
BMD was higher in 
patients with diabetes at 
the femoral neck, hip, 
and spine, but not 
forearm compared to 
controls.  
Pan et al. 2014 
(88). 
Meta-analysis. 25 observational 
studies (2715 
females with 965 
patients with T1D 
and 1230 males with 
537 patients with 
T1D). 
BMD was lower in men 
with T1D at the spine 
and femur compared to 
controls. BMD was 
lower in women with 
T1D at the hip, femur, 
and forearm compared 
to controls. 
Vestergaard 
2007 (11). 
Meta-analysis 
of 
observational 
studies. 
62 observational 
studies. 
Spine Z-score was -0.22 
and 0.41 and Hip Z-
score was -0.37 and 0.27 
in patients with T1D and 
T2D, respectively 
compared to controls. 
Studies comparing Dual energy x-ray absorptiometry between patients with 
type 1 and type 2 diabetes 
Bridges et al. 
2005 (92). 
Cross-
sectional. 
35 men with T1D, 90 
men with T2D, and 
55 controls. 
No difference in 
peripheral BMD 
between patients with 
T1D and T2D. 
Jehle et al. 
1998 (91). 
Cross-
sectional. 
27 patients with 
T1D, 25 patients 
with T2D, and 100 
BMD of the hip and 
spine was lower in T1D 
compared to T2D. 
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controls. 
Leidig-
Bruckner et al. 
2014 (93). 
Cross-
sectional. 
139 patients with 
T1D, 243 patients 
with T2D, and 504 
controls. 
BMD was not different 
between patients with 
T1D and T2D. 
Rakic et al. 
2006 (89). 
Cross-
sectional. 
34 patients with 
T1D, 194 patients 
with T2D, and 228 
controls. 
Hip and femoral neck 
BMD was lower in 
patients with T1D 
compared to patients 
with T2D. 
Tuominen et 
al. 1999 (90). 
Cross-
sectional.  
56 patients with 
T1D, 68 patients 
with T2D, and 498 
controls. 
BMD at the femur was 
lower in patients with 
T1D compared to 
patients with T2D and 
controls. 
High resolution peripheral quantitative computed tomography 
Farr et al. 2014 
(102). 
Cross-
sectional 
30 patients with T2D 
and 30 controls. 
Increased cortical 
thickness and trabecular 
number at the radius in 
patients with T2D 
compared to controls. 
Increased cortical 
thickness at the radius. 
Patsch et al. 
2013 (100). 
Cross-
sectional. 
20 patients with 
diabetes without 
fracture, 20 patients 
with diabetes with 
fracture 20 controls 
without fracture, 20 
controls with 
fracture. 
Greater cortical porosity 
in patients with diabetes 
with fracture than those 
without. 
Shanbhogue et 
al. 2015 (103). 
Cross-
sectional. 
55 patients with T1D 
and 55 controls. 
Patients with T1D had 
higher total bone area, 
trabecular area and 
lower vBMD and 
cortical vBMD at the 
radius. Patients with 
T1D and microvascular 
disease had a lower 
vBMD at both radius 
and tibia compared to 
patients with T2D 
without microvascular 
disease. 
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Shu et al. 2012 
(101). 
Cross-
sectional. 
25 postmenopausal 
women with T2D 
and 25 controls. 
No difference between 
patients with T2D and 
controls in HRpQCT 
parameters. 
Quantitative computed tomography 
Heilmeier et al. 
2015 (106). 
Cross-
sectional 
80 postmenopausal 
women (20 patients 
with T2D and a prior 
fragility fracture, 20 
patients with T2D 
without a fragility 
fracture, 40 
controls). 
Patients with T2D and 
fracture had lower 
femoral vBMD and 
thinner cortex compared 
to patients with T2D 
without fracture. 
Magnetic resonance imaging 
Abdalrahaman 
et al. 2015 
(107) 
Cross-
sectional. 
30 women with T1D 
and 28 controls. 
Bone marrow volume 
was lower and 
trabecular spacing was 
higher in women with 
T1D.  
Table 1. Studies that investigate patients with diabetes by DXA, HRpQCT, QCT, 
and MRI. 
 
Table 2 present the characteristics of the different scanning techniques. The most 
standardized scan, DXA, which also is the only one that predicts incident fractures, 
is of poor use in patients with diabetes. New visualizing bone scans as the HRpQCT, 
QCT, and MRI may be able to predict fractures in diabetes, however, the scans only 
visualize bone structure and not bone metabolism. Furthermore, besides MRI; DXA, 
CT, QCT, and HRpQCT all visualize the mineralized matrix, i.e. the calcium 
containing matrix, and in diabetes perhaps the non-mineralized matrix may also be 
affected. In general little is known about the effect of long term elevated p-glucose 
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in diabetes and microvascular complications on the structure of bone and the relation 
to bone turnover.   
 
Scanning 
technique 
Radiation Sites measurable Resolution Measures Fracture 
predictor 
DXA Low Central and 
peripheral 
Low Bone mineral 
density  
Yes 
HRpQCT Very low Peripheral High Bone mineral 
density and 
bone micro 
architecture.  
Maybe 
QCT High Central and 
peripheral 
Medium Bone mineral 
density and 
bone micro 
architecture. 
Maybe 
MRI None Central and 
peripheral 
High Bone micro 
architecture 
Maybe 
Table 2. Overview of pros and cons of the visualizing bone scans (108, 109). 
 
1.6 BONE TISSUE BIOPSIES 
With unclear results of structural and density bone scans, the solution may be inside 
the bone tissue. Bone tissue biopsies may both provide structural, dynamic, and 
mechanical loading parameters. However, few and small bone biopsy studies are 
conducted on patients with diabetes. Two human studies find low bone turnover in 
diabetes (95, 110). In these studies bone biopsies are performed on 8 and 5 patients 
with diabetes, respectively (95, 110). However, another study in 18 patients with 
T1D does not show any differences in static or dynamic histomorphometric 
variables compared to non-diabetes subjects (111).  Patients in this study were well 
controlled with a with a mean HbA1c of 6.8 % (111), which may influence the 
results as the fracture risk is highest in levels above 9 % (81). Evidence from bone 
biopsies is conflicting since no comparison between patients with T1D and T2D has 
been published. Bone biopsies may contain valuable information but are difficult to 
obtain. 
Another invasive technique is microindentation, which allows a quantification of 
bone material strength (BMS) with no removal of bone (112, 113). A single study is 
performed in patients with T2D (102). It reveals decreased BMS in patients with 
T2D compared to controls, even though the HbA1c is decently controlled over the 
previous ten years (7.4 %) and the BMS is negatively correlated to it (102).  
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1.7 BIOCHEMICAL BONE MARKERS AND DIABETES 
Bone metabolism may be measured by biochemical markers of bone turnover. The 
markers represent different processes in bone turnover from collagen synthesis 
(procollagen type 1 amino terminal propeptide (P1NP)) and degradation (C-terminal 
cross-linked telopeptide of type-I collagen (CTX)) to markers secreted by bone cells 
(osteocalcin (OC) and bone specific alkaline phosphatase (BAP)) (114). Thus bone 
markers may reflect different parts of bone turnover as well as different 
compartments.  In paper 1 (115), paper 2 (114), and paper 3 (116) biochemical bone 
markers in diabetes are explained in detail. Both serum and plasma samples may 
have been used in the studies included in paper 1-3 and in the thesis these samples 
are described as serum samples (s-). Bone turnover markers include formative 
markers (OC, BAP, P1NP), resorptive markers (CTX and N-terminal cross-linked 
telopeptide of type-I collagen (NTX)), important players of bone turnover (RANKL, 
OPG, PTH, and sclerostin), and markers of other metabolic pathways (IGF-1, 
pentosidine, and adiponectin). The qualitative evaluation of previous studies in the 
narrative review of observational studies, paper 1 (115), revealed that s-CTX and s-
OC seem to be lower in patients with T1D, while s-tartrate resistant acid 
phosphatase (TRAP) and s-OC seem lower and s-sclerostin and urine (u-) NTX 
higher in patients with T2D in comparison to subjects without diabetes. 
Furthermore, bone turnover markers seem stable over time in patients with T1D 
(117-119) and even after intensive insulin therapy (120), whereas the s-CTX as the 
only bone marker seems to increase over time in patients with T2D (117, 119). The 
apparently stable bone turnover suggests constant bone affection in diabetes. In 
patients with T2D, glycemic control may decrease bone resorption (121-124) and 
the metabolic status may thus affect bone turnover. The differences in biochemical 
bone markers between patients with diabetes and non-diabetes subjects are 
quantified in a meta-analysis based on observational studies, paper 2 (114). S-OC, s-
CTX, and s-25 hydroxy vitamin D (25 OHD) levels are decreased, whereas s-
phosphate is increased in patients with diabetes compared to non-diabetes subjects. 
It is unclear whether or not the increase in phosphate is related to an impaired FGF-
23 secretion. When stratifying by diabetes type fewer studies are included, but s-OC 
levels are significantly decreased in patients with T1D and borderline significantly 
decreased in patients with T2D (p=0.06) compared to non-diabetes subjects. 
Furthermore, s-phosphate is only increased in patients with T2D and not in patients 
with T1D compared to non-diabetes subjects. Specific markers of bone turnover, s-
CTX and s-OC, seem to be decreased in patients with diabetes, whereas other 
markers displayed no differences. Although CTX is decreased in diabetes patients 
compared to non-diabetes subjects, NTX, a marker reflecting resorption by 
degradation of the same molecule as CTX, is borderline increased in patients with 
diabetes (p=0.06). The discrepancy between CTX and NTX is a paradox, but may be 
explained by differences in patient characteristics in the evaluated studies and half-
life of the bone turnover marker, although it previously has been concluded that no 
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difference is present between NTX and CTX independent of measurement in serum 
or urine (125) . 
Bone turnover markers displayed large inter-study heterogeneity in the meta-
analysis, which may be a result of the variety of assays as well as differences in the 
assessed populations.  However, the studies compare diabetes and non-diabetes 
populations with the same assays and find the patients with diabetes and subjects 
without diabetes comparable. The heterogeneity may be explained by the 
aforementioned factors; however it is unclear whether specific diabetes related 
characteristic as medication use, glycemic level and so forth could be the real 
explanation of the heterogeneity. 
The systematic review, paper 3 (116), updated the literature search and further 
examined the relation between bone markers and fracture and the influence of 
antidiabetics on the markers. Bone turnover markers still seem decreased in both 
patients with T1D and T2D; however, s-BAP tends to be increased, which may 
reflect a hypermineralization of bone. Further, decreased levels of s-OC (126), s-
IGF-1 (126-128), increased levels of s-sclerostin (127, 129) and an imbalance in 
bone turnover by high s-CTX and low s-P1NP (130) are all associated with 
prevalent fractures. Recently, in an abstract presented at the European Association 
for the Study of Diabetes (EASD) 2014 in Vienna, s-IGF-1 seemed associated with 
incident fractures in postmenopausal women with T2D (131). These potential 
fracture predictive markers all relate to an impaired bone formation and low bone 
turnover. Antidiabetic treatment may also affect bone turnover: In randomized 
controlled trials glitazone treatment increased s-CTX (132-135) and increased s-
sclerostin levels (134). Furthermore, dipeptidyl peptidase IV (DPP IV) inhibitors 
decreased the resorptive marker u-deoxypyridinoline (DPD) whereas metformin did 
not change u-DPD or s-OC (136). Further studies are needed to examine the effects 
of antidiabetic treatments on bone turnover markers as they may influence it.  
It is unknown whether the apparent low bone turnover is caused by a specific 
pathway (RANKL/OPG, Wnt, and FGF-23) and if the bone turnover is affected 
differently in patients with T1D and T2D. 
 
1.71 GLUCOSE AND BONE TURNOVER MARKERS 
Bone turnover markers display large heterogeneity in diabetes (114), which may be 
caused by different p-glucose levels. An OGTT decreases both resorptive (s-CTX) 
and formative markers (s-P1NP and s-OC) within twenty minutes after ingestion in 
healthy young individuals (137). Similar effects are also seen by food ingestion 
(138). Furthermore, s-CTX decreases both in an intravenous glucose tolerance test 
(IVGTT) and in an OGTT in healthy women; however, the decrease is significantly 
greater after an OGTT (139). During an OGTT s-CTX decreased significantly in 
postmenopausal women with T2D, however the decrease was significantly smaller 
than in normoglycemic postmenopausal women and s-OPG levels were unaffected 
(140). The effects of OGTT on bone turnover markers are abolished by the 
somatostatin analogue, octreotide (137), reflecting a possible link to insulin 
secretion or gastrointestinal hormones. This link may be via the glucagon-like 
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peptide 2 (GLP-2), which when subcutaneously injected reduces bone resorption 
markers, whereas bone resorption is unaffected by GLP-1 injection (138). Another 
possibility is the gastric hormone ghrelin. However, whether the effect of glucose is 
direct or indirect through gastrointestinal hormones is yet unknown. In diabetes it is 
not known whether increasing p-glucose levels decrease bone turnover markers and 
if so by which bone regulatory pathway. 
In vitro studies show effects of high glucose levels on osteoclasts and osteoblasts. In 
osteoclasts, high glucose levels inhibited RANKL-induced osteoclastogenesis (141) 
and decreased Tartrate resistant acid phosphatase (TRAP) activity and the pit 
resorption area for osteoclasts (142). Furthermore, high glucose levels increase 
mineralization at 12 mM levels and especially at 24 mM levels (Figure 6) and 
hyperosmotic stress induces over expression of Toll like receptors in osteoblasts, 
which are known to cause insulin resistance (143).  
 
 
Figure 6. High levels of glucose on the biomineralization of osteoblastic cells at 7 
and 14 days of treatment (From Garcia-Hernandez with permission) (143). 
 
In contrast, another study showed that hyperglycemia and high osmotic pressure for 
24 hours increased the production of collagen type I in osteoblasts and decreased the 
expression of BAP (144), thus the effects of glucose on mineralization are unclear. 
Osteocyte like cells exposed to high glucose levels decrease expression of sclerostin 
protein, but not RANKL (145) and osteocytes may thus also be affected. The in vitro 
studies highlight a direct effect of glucose on bone cells, which may support a 
change in biochemical properties brought about by the hyperglycemia per se. 
Further research is needed to determine the relationship and mechanisms. 
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1.72 OSTEOCALCIN AND GLUCOSE 
OC, a product of bone formation, is in animal models shown to reverse insulin 
resistance, hyperglycemia, and obesity. Furthermore, the undercarboxylated form 
stimulates proliferation of beta-cells and increases insulin release and sensitivity. A 
forward loop may exist as insulin may decrease OPG secretion and enhance OC 
gene expression and thereby promote release of undercarboxylated OC (ucOC) 
during the acidic conditions under bone resorption, which again promotes insulin 
release and insulin sensitivity (Figure 7). In humans, s-OC is associated with insulin 
sensitivity, p-glucose levels, HbA1c, and diabetes (146, 147). However, evidence is 
still too limited in humans to determine an effect (148). 
 
 
 
Figure 7. The feedforward regulation of osteocalcin, bone resorption, and insulin 
(From Clemens et al. with permission) (147). 
 
1.8 ANTIDIABETICS AND FRACTURES 
As hyperglycemia may both exert effects on bone turnover and increase fracture 
risk, p-glucose lowering may be the answer to prevent diabetic bone disease. The 
evidence is limited as few studies have examined the effect of antidiabetics on 
fractures. Glitazones are associated with an increased fracture risk in patients with 
T2D (149-151). Metformin and sulphonylureas are associated with a decreased risk 
of fractures, whereas insulin and other types of oral antidiabetics have neutral 
outcomes (65). However, other studies show neutral effects of metformin (152-154) 
and of sulphonylureas (76, 152). The more recent products as the dipeptidyl 
peptidase IV DPP-IV inhibitors have shown neutral outcomes (155, 156) and may 
even protect against fractures as reported in a meta-analysis of randomized 
controlled trials – however, the mean trial duration is as short as 35 weeks (157). 
Glucagon-like Peptide-1 receptor agonists (GLP-1 RA) have shown neutral effects 
in a meta-analysis of randomized controlled trials (158) and in an observational 
study (159). However, another meta-analysis of randomized controlled trials divides 
the GLP-1 RA treatment by liraglutide and exenatide and finds opposite effects; 
liraglutide decrease fracture risk and exenatide increase fracture risk (160). Again, 
the mean trial duration is short (158, 160). 
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The effects of antidiabetics may simply be caused by tighter glycemic regulation. 
However, besides the harm of glitazones it is unknown whether a specific treatment 
is optimal for bone health in diabetes. 
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1.9 SUMMARY 
Figure 8 depicts the factors that may influence the increased fracture risk in diabetes 
patients. In summary diabetes is associated with an increased risk of fracture, which 
is not explained by BMD by DXA, FRAX, diabetes complications or falls although 
they may contribute to it. AGE products, TBS, increased cortical porosity, increased 
s-sclerostin levels, and HbA1c may all contribute to the increased fracture risk. 
However, at present only associations have been described and further studies are 
thus needed. Treatment with glitazones has a detrimental effect on bone in diabetes 
patients, whereas other antidiabetic treatments seem safe. Based on s-OC and s-CTX 
bone formation and resorption seem to be decreased in diabetes patients. However it 
is unknown why the turnover is decreased although effects of glucose on both 
osteoclasts and osteoblasts may be responsible.  
 
 
 
Figure 8. Factors that may influence the risk of fracture in diabetes patients. OPG: 
Osteoprotegerin, AGE: Advanced Glycation End, TBS: Trabecular bone score, 
BMD: Bone mineral density, FRAX: Fracture Risk Assessment Tool. Blue arrows 
indicate relationships. Red arrows indicate inhibitory effects. Green arrows indicate 
a positive effect or secretion. X mark associations that do not explain the increased 
fracture risk in diabetes patients. ↓ marks a decrease compared to subjects without 
diabetes. ↑ marks an increase compared to subjects without diabetes. 
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2. AIM AND HYPOTHESIS 
Primary hypotheses: 
I. Patients with type 1 and type 2 diabetes differ in bone density 
measured by BMD, where BMD is decreased in type 1 diabetes. 
II. To explain the expected decreased in BMD in patients with type 1 
diabetes they have higher bone turnover measured by circulating 
biochemical markers compared to patients with type 2 diabetes. 
Secondary hypotheses 
III. Bone turnover markers are decreased in patients with diabetes 
compared to non-diabetes controls. 
IV. HbA1c levels predict fractures in patients with diabetes. 
V. Increasing plasma glucose decreases circulating bone turnover 
markers. 
 
The aims of the thesis were: 
I. To examine differences in bone structure between patients with type 1 
and type 2 diabetes by DXA and HRpQCT. 
II. To examine differences in bone turnover between patients with type 1 
and type 2 diabetes by biochemical markers. 
III. To evaluate whether medication use and biochemical parameters are 
associated with fracture risk in patients with diabetes. 
IV. To investigate differences in bone turnover markers between patients 
with diabetes and controls. 
V. To examine the relationship between plasma glucose and bone 
turnover markers in patients with diabetes. 
VI. To establish whether the effect of glucose on bone turnover markers is 
direct or mediated by gastrointestinal absorption of glucose.  
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3. PAPERS 
 
This PhD resulted in seven papers. 
 
Paper 1 Diabetes, biochemical markers of bone turnover, diabetes control, 
and bone 
 Starup-Linde J  
 Frontiers in Endocrinology, volume 4 March 2013 
A literature study on the difference in bone turnover markers 
between patients with diabetes and controls. 
 
Paper 2 Biochemical markers of bone turnover in diabetes patients – a meta-
analysis, and a methodological study on the effects of glucose on 
bone markers 
 Starup-Linde J, Eriksen SA, Lykkeboe S, Handberg A, Vestergaard 
P 
 Osteoporosis International, Volume 25 June 2014 
 A meta-analysis on the difference in bone turnover markers between 
patients with diabetes and controls. 
 
Paper 3 Biochemical bone turnover markers in diabetes mellitus – A 
systematic review 
 Starup-Linde J, Vestergaard P 
 Bone, Available online February 2015 
A systematic literature study on biochemical bone turnover makers 
in diabetes.  
 
Paper 4 Low-density lipoprotein cholesterol is associated with fracture risk 
in diabetes patients – a nested case-control study. 
 Starup-Linde J, Gregersen S, Vestergaard P 
 Manuscript  
A case control study examining possible fracture predictors in 
patients with diabetes. 
 
Paper 5 Differences in biochemical bone markers by diabetes type and the 
impact of glucose 
Starup-Linde J, Lykkeboe S, Gregersen S, Hauge E-M, Langdahl 
BL, Handberg A,  
Vestergaard P 
Manuscript submitted  
A cross-sectional study examining differences in biochemical bone 
markers between patients with T1D and T2D and the influence of 
glucose. 
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Paper 6 Bone structure and predictors of fracture in type 1 and type 2 
diabetes 
Starup-Linde J, Lykkeboe S, Gregersen S, Hauge E-M, Langdahl 
BL, Handberg A, Vestergaard P 
Manuscript submitted  
A cross-sectional study examining differences in bone structure 
between patients with T1D and T2D and possible fracture 
predictors. 
 
Paper 7 The effect of glucose on bone – direct or indirect? 
Westberg-Rasmussen S, Starup-Linde J, Hermansen K, Vestergaard 
P, Gregersen S. 
 Manuscript in preparation 
An interventional study comparing the bone turnover marker 
response by oral ingestion and intravenous infusion of glucose. 
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4. METHODS 
4.1 LITERATURE SEARCH 
Literature searches were performed for the reviews and meta-analysis (114-116).  
 
4.11 THE NARRATIVE REVIEW (PAPER 1) 
A literature search was first performed in August 2012 with the assistance of a 
research librarian. Results from this search were used in the narrative review, paper 
1 (115). The databases searched were Medline at Pubmed, Embase, Cinahl, 
Svemed+, Cochrane Library, and Bibliotek.dk. If applicable the search was 
conducted using the thesaurus with the search terms: “Diabetes mellitus” or 
“Diabetes mellitus type 1” or “Insulin dependent diabetes mellitus”or “Diabetes 
mellitus type 2” or “Non insulin dependent diabetes mellitus” or “Hemoglobin A 
glycosylated” or “HbA1c and “Bone” or “Bone and Bones” or “Bone diseases” or 
“Bone turnover” ”. Records were eligible if they were observational and examined 
biochemical markers of bone turnover in patients with diabetes. If records used the 
same population only the best study based on design, methodology, and number 
assessed markers, evaluated by J Starup-Linde, was included. Records assessing the 
effect of different medications were excluded. In total 1,188 records were retrieved 
after the removal of duplicates. All records were screened by title and abstract for 
the eligibility criteria and 1,113 records were removed. 75 records were assessed for 
inclusion by full text screening with the above described eligibility criteria. In total 
43 records were included (32 of cross-sectional design and 11 of a prospective 
design).  
If the patients with diabetes were grouped as insulin treated diabetes (ITD) or non-
insulin treated diabetes (NITD) they were interpreted as patients with T1D and T2D, 
respectively. NITD cannot contain patients with T1D, however ITD may contain 
patients with T2D. 
 
4.12 THE META-ANALYSIS (PAPER 2) 
The same literature search profile used in paper 1 (115) was performed for paper 2 
(114). The eligibility criteria for the meta-analysis were records comparing 
biochemical bone turnover markers between patients with diabetes and controls. 
Studies had to be observational and studies assessing different medications or 
reusing populations were excluded. Studies were also included in the meta-
regression analyses if they evaluated patients with diabetes but did not compare to a 
control group. 1,118 records were screened by title and abstract resulting in 
assessment of 75 records. 22 studies were included in the meta-analysis and 
additional 18 studies were included in the meta-regression. The study selection is 
presented in Figure 9. 
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Figure 9. The steps of selection- from Starup-Linde et al. 2014 with permission 
(114). 18 records assessing bone turnover markers in patients with diabetes but with 
no comparison to a control group were included in the meta-regression. 
 
4.13 THE SYSTEMATIC REVIEW (PAPER 3) 
For the systematic review (116) a systematic literature search was conducted in 
August 2014 using the databases Medline at Pubmed and Embase. Medline at 
Pubmed was searched by the MESH term “Diabetes Mellitus” and the free text term 
“bone turnover markers”. Embase was searched by the thesaurus using the terms 
“Diabetes Mellitus” and “bone turnover” with the limitation of human studies. 611 
records were retrieved. Figure 10 present the steps of selection. The difference in the 
number of publications included in section 4.11, 4.12 and 4.13 is due to differences 
in eligibility criteria. For this search they are described below. 
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Figure 10. The steps of selection –from Starup-Linde et al. 2015with permission  
(116). 
 
The eligibility criteria for inclusion were assessment of bone turnover markers in 
either patients with T1D or T2D. If records used the same population the best study 
based on design, methodology, and number assessed markers, rated by J Starup-
Linde, was included. No records were excluded on the basis of treatment by 
antidiabetics, antiresorptives, bone anabolic treatment or statins as opposed to the 
literature search described in section 4.11. The meta-analysis was included, thus 
records presented herein were not included (114). Data was extracted from the 
records, which include study design, randomization and intervention (if applicable), 
HbA1c, study duration, number of participants, diabetes type, diabetes assessment, 
bone turnover markers, fasting status at blood sample collection, and renal disease. 
Study quality was not assessed as both observational studies and intervention studies 
were included.  
Two additional records were added as they were not included in the systematic 
literature search but found in their respective journal and were within in the scope of 
the systematic review. 613 records were screened for eligibility by title and abstract, 
which lead to 116 potential records. These were evaluated for eligibility by full text 
assessment leading to 47 included studies.   
 
4.14 THE SYSTEMATIC LITERATURE SEARCH FOR THE THESIS 
A systematic literature search was conducted for the thesis . Medline at Pubmed and 
Embase were searched in the period June 2014 till February 2015 on the search 
terms “diabetes” and “fracture” giving 229 records at Medline at Pubmed and 567 
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records at Embase. Furthermore, a search was performed to find previous studies 
assessing bone structure differences between diabetes types by the search terms 
“type 1 diabetes”, “type 2 diabetes”, and “bone mineral density” with no limitations 
leading to 44 records at Medline at Pubmed and 179 records at Embase. These 
results were pooled with the results of the searches described in sections 4.11 and 
4.13 and give basis for the systematic literature search for the thesis. 
 
4.2 THE META-ANALYSIS (PAPER 2) 
Data from the 22 records for meta-analysis and additional 18 records for meta-
regression were extracted and tabulated independently by J Starup-Linde and SA 
Eriksen. The data extracted included age, BMI, gender, diabetes type, study design, 
fasting status at the time of blood sample, follow up years (if applicable), HbA1c, 
OC, BAP, alkaline phosphatase (AP), collagen type 1C propeptide (CICP), CTX, 
NTX, DPD, calcium, phosphate,  25 hydroxy D vitamin (25 OHD vitamin), and 
PTH. Data was sought on other bone markers, but it was not possible to conduct a 
meaningful meta-analysis. ITD patients were grouped as patients with T1D and 
NITD as patients with T2D. The quality of the studies was ascertained by the 
Newcastle Ottawa Scale (NOS) for cohort studies and a modified scale for cross-
sectional studies. J Starup-Linde and SA Eriksen scored the studies and P 
Vestergaard settled disagreements. 
Mean values and 95 % confidence intervals of bone turnover markers were tabulated 
and by random effects modeling common weighted estimates were calculated. 
Pooled analyses were only performed if three study groups were available. 
Publication bias was assessed visually by funnel plot and also by the Eggers test. 
Heterogeneity between studies was calculated by I
2
 test. Analyses were also 
stratified by diabetes type. Meta-regression analyses were performed using the 
variables; age, BMI, gender, HbA1c, diabetes, diabetes duration, fasting status, and 
creatinine levels.    
Calculations were performed using The RevMan software program and STATA 8.  
 
4.3 THE METHODOLOGICAL STUDY ON THE EFFECTS OF 
GLUCOSE ADDED TO SERUM ON THE MEASUREMENTS OF 
BONE TURNOVER MARKERS (PAPER 2) 
A methodological study was conducted at the Department of Clinical Biochemistry, 
Aalborg University Hospital. From two healthy individuals a fasting blood sample 
was drawn and fasting glucose was measured (5mM in each sample). To each 
sample glucose was added to final glucose concentrations of 5 mM (reference), 10 
mM, 15 mM, and 25 mM. The reference and glucose supplemented samples were 
incubated at 37 °C and s-CTX, s-P1NP, and s-OC were measured at time 0, after 1 
hour, after 2 hours, and after 3 hours. Bone markers were measured on an automated 
Cobas analyzer (Roche Diagnostics, Mannheim Germany). The coefficients of 
variation for CTX, P1NP, and OC were less than 6 %, less than 4 %, and less than 2 
%, respectively. Serum stability was 8 hours for CTX and 24 hours for P1NP and 
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OC, as provided by the manufacturer. Multiple linear regressions were performed 
using Microsoft Excel 2007 and SPSS 20.0.  
 
4.4 THE CASE CONTROL STUDY (PAPER 4) 
The STROBE guideline for reporting of case-control studies was followed (161). 
The study was approved by the Danish Data Protection Agency. 
 
4.41 DESIGN 
The study was designed as a nested case control study in a cohort of patients with 
diabetes. Patients with diabetes mellitus were sampled from a register, based on the 
diagnosis appearing in the period January 1 1977 to December 31 2011. Cases were 
patients with a fracture subsequent to the diagnosis of diabetes in the period 2008-
2011 and controls were patients with diabetes without a fracture in the same time 
period. 
 
4.42 DIABETES ASSESSMENT AND FRACTURE ASSESSMENT  
From The Danish National Hospital Discharge Register in the time period 01-01-
1977- 31-12-2011 all patients with diabetes were extracted using International 
Classification of Diseases (ICD)-10 (E10-E14) and ICD-8 codes (249-250). The 
Danish National Hospital Discharge Register covers all inpatient contacts from 1977 
and from 1995 also all outpatient visits at hospitals, outpatient clinics, and 
emergency rooms. ICD 8 and ICD 10 codes were used to extract specific diagnoses. 
Cases were defined by ICD-10 fracture codes (ICD-10 codes: S02.0–S02.9, S07.0–
S07.9, S12.0–S12.9, S22.0–S22.9, S32.0–S32.8, S42.0–S42.9, S52.0–S52.9, S62.0–
S62.9, S72.0–S72.9, S82.0–S82.9, and S92.0–S92.9). The fracture codes cover both 
low and high energy fractures. Due to the unique social security number it was 
possible to link the diagnosis of diabetes and a diagnosis of fracture. 
  
4.43 EXPOSURE VARIABLES 
Anatomical Therapeutic Chemical Classification system (ATC) codes and 
Nomenclature for Properties and Units (NPU) codes were used to extract data on 
prescription reimbursement and measured biochemical parameters. NPU coding is 
an international classification system used in Clinical Laboratory Sciences. 
Information on exposure variables were obtained from The Danish National 
Hospital Discharge Register regarding comorbidities, the Central Region of Jutland, 
biochemical parameters (2008-2011) and medication use from the prescription 
registry (2008-2011). Only data on redeemed drugs on prescription was available 
and not over-the-counter drugs. The age of the patients was defined as the age at 
January 1, 2008. The duration of diabetes was defined as the time from diabetes 
diagnosis to the end of the prescription register, December 31, 2011. Data on 
biochemical markers were obtained from the hospitals in the Central Region of 
Denmark, thus the markers were for clinical use and not available for all patients. 
LDL-cholesterol was calculated by the Friedewald formula. Statin duration was 
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calculated as the time span between first redeemed prescription and to time of a 
fracture (for cases) or to the end of follow up, December 31, 2011 (for controls). 
Drug users of either nicotine substitution, vareniclin, bupropion, inhaled β-agonists, 
inhaled anticholinergics or inhaled corticosteroids were defined as smokers. Users of 
antihypertensive drugs were defined as having hypertension. Users of 
bisphosphonates, teriparatide, strontium ranelate, denosumab or hormone 
replacement therapy were grouped as one. An alcohol-related diagnosis was defined 
as an ICD-10 code F10 or ICD-8 code 303. 
 
4.44 THE STUDY POPULATION 
156,698 patients with diabetes were available from The Danish National Hospital 
Discharge Register. 29,929 of these had data on pharmaceutical use from the 
prescription registry. Individuals with nephropathy were excluded due to the 
detrimental effects on bone health. 2,627 patients with diabetes had information on 
selected biochemical markers. In total 2,627 patients with diabetes were available 
for analyses. 
 
4.45 STATISTICAL ANALYSIS 
The STATA 8 statistics package was used. Use of a pharmaceutical was categorized 
as (yes/no) and biochemical parameters were processed as numerical values. An 
unadjusted and an adjusted case control analysis were performed using logistic 
regression. Results are expressed as odds ratios (OR). The term risk will be used 
synonymously with OR as fracture is a rare outcome. Subgroup analyses were 
performed by diabetes type and by LDL-cholesterol levels grouped in eight 
quantiles. The division into eight quantiles was performed to investigate differences 
between the lowest and highest levels of LDL-cholesterol. Statin duration was 
included as a variable in separate analyses.  
 
4.5 THE CLINICAL STUDY (PAPER 5 AND 6)  
The STROBE guideline for reporting of cross-sectional studies was followed (161). 
The clinical study was registered at ClinicalTrials.gov (NCT01870557). The study 
was approved by the Danish Data Protection Agency and the Ethics Committee of 
the Central Denmark Region. The clinical study was conducted according to the 
Helsinki Declaration.  
 
4.51 DESIGN, SETTING, AND PARTICIPANTS 
A clinical study was performed to investigate differences in bone turnover markers 
and bone structural scans between patients with T1D and T2D. Also, data on 
fractures was collected to investigate potential fracture predictors. To evaluate this, a 
cross-sectional design was used. Furthermore, a case control design was used to 
analyze associations between fractures and bone markers. The study was a 
multicenter study conducted at two Danish University Hospitals. All patients were 
recruited from the outpatient clinics at the University Hospitals. From the 
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Department of Endocrinology and Internal Medicine, Aarhus University Hospital 
121 patients were included and from the Department of Endocrinology, Aalborg 
University Hospital 76 patients were included. Electronic patient journals were 
screened for eligibility and exclusion criteria and patients were asked if they were 
interested in the study at an outpatient clinic visit. Possible participants were invited 
to give informed consent and were interviewed for eligibility in the study. Two 
patients were excluded due to use of hormone replacement therapy and two patients 
withdrew their informed consent shortly after enrolment. Patients were recruited and 
included consecutively. The eligibility criteria for the patients were that they had to 
be diagnosed by a physician with diabetes mellitus, to be at least 50 years old, to be 
in antidiabetic treatment (oral antidiabetics, insulin treatment or GLP-1-RA), and 
report a body mass index (BMI) between 19 kg/m
2 
and 35 kg/m
2
. BMI ranged from 
18 kg/m
2 
to 40 kg/m
2
 at the examination. Patients were not excluded for this reason. 
All patients presented a recent HbA1c of at least 49 mmol/mol (6.6 %) and had a 
relatively stable HbA1c within the last six months (± 1% based on the DCCT scale). 
Furthermore, all patients had a recent estimated glomerular filtration rate (eGFR) as 
a minimum of 50 ml/minute.   
Patients were excluded if diagnosed with diseases affecting bone including renal 
dysfunction, uncontrolled thyroid disease, NYHA class IV heart failure, and cancer. 
Patients with a metal implant at both ankles and wrists were excluded. Patients with 
a recent HbA1c above 85 mmol/mol were excluded. Individuals treated with 
antiepileptics, oral glucocorticoids, lithium, antiresorptive treatment, oral estrogen 
treatment, and bone anabolic treatment were excluded. One patient was treated with 
bisphosphonate a month before inclusion, but as bone turnover markers (p-CTX, p-
P1NP, and p-OC) were not different from other patients; the individual remained in 
the study. Two of the female patients had ongoing menstrual cycles all others were 
postmenopausal. In general, patients were in stable antidiabetic treatment with no 
recent drug type or dosage changes. 
 
4.52 BLOOD SAMPLE AND URINE SAMPLING 
All patients had a non-fasting blood sample drawn and all but two delivered a 24 
hour urinary sample. Blood samples were generally drawn in the morning, obtaining 
plasma samples for the conventional biochemical tests:  Glucose, glycated 
hemoglobin (HbA1c), LDL-cholesterol, high-density lipoprotein (HDL)-cholesterol, 
total-cholesterol, triglycerides, 25 OH vitamin D, creatinine, sodium, and potassium. 
These parameters were measured at the Department of Clinical Biochemistry at the 
respective University Hospital. The remaining samples were divided into aliquots 
and stored at −80°C.  
Freshly thawed samples blinded to clinical status for the technician was used for 
measuring bone turnover markers. All bone turnover markers were analyzed on 
EDTA-plasma, except for RANKL and OPG where serum was used. P-CTX, p-OC, 
and p-P1NP were measured as single determinations on an automated Cobas 
analyzer from Roche Diagnostics (Mannheim, Germany). P-.ucOC (Takara Bio Inc, 
Otsu, Japan), p-FGF-23 (Immutopics, San Clemente, USA), p-sclerostin/s-OPG 
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(Biomedica, Vienna, Austria) and free non-OPG-bound s-RANKL (Biomedica, 
Vienna, Austria) were measured as ELISA double determinations. The analytical 
coefficients of variation were according to the manufacturers as follows: CTX < 6%, 
P1NP < 4%, OC < 2%, ucOC < 10%, FGF-23 < 5%, Sclerostin < 10%, RANKL < 
3%, OPG < 5%. Measurements were performed in clinical biochemical laboratories 
accredited according to ISO 15189. 
 
4.53 DXA (PAPER 6) 
Measurements of areal BMD (aBMD) were performed using DXA scans. aBMD is a 
common used predictor of fracture (9). All patients were scanned at the spine, left 
hip, and right radius on the DXA scan. All scans were performed by trained and 
experienced staff at a clinical department. A single patient experienced extreme 
dizziness during the scan and it was aborted. At the Aarhus University Hospital 
center Hologic scans were performed using two different Hologic Discovery 
scanners and at the Aalborg University Hospital Center scans were performed using 
two different Lunar Prodigy scanners. To obtain information on precision coefficient 
of variation (CV) and difference in measured values a Hologic Discovery phantom 
was scanned ten times at each scanner. The precision CVs were 1 % for both 
Hologic Discovery and Lunar Prodigy scanners. One of the Hologic Discovery 
scanner selected as reference (based on the number of patients, n = 108). The Lunar 
Prodigy scanners measured BMD 14 % and 15 % significantly higher than the 
reference and the other Hologic Discovery scanner measured 2 % significantly 
higher. BMD was calculated based on the conversion factors reported above. T-
scores and Z-scores were calculated based on the paper of Kelly et al. (162). The 
calculated T-scores were -0.23, -0.40 lower at the hip and femur, respectively 
compared with 21 randomly selected values from the discovery machine. Spine T-
scores did not differ between calculated values and values directly from the 
scanners, whereas the difference in radius T-score was 0.47. The Z-scores differed 
by -0.04 at the hip, -0.15 at the femur, 0.39 at the spine, and 2.52 at the radius. Due 
to the large variation between calculated and directly measured T- and Z-scores at 
the radius, BMD is given instead. Reported hip and femur T-scores are corrected by 
the factors -0.23 and -0.40, respectively. 
 
4.54 HRPQCT (PAPER 6) 
The HRpQCT scan (Xtreme CT, Scanco Medical, Switzerland) volumetric BMD 
(vBMD) and the finite element analysis provides functional parameters of the tissue 
(163). Patients included at Aarhus University Hospital were scanned using HRpQCT 
at the right radius and right tibia. If a prior fracture was present at either of these 
sites or pain made it impossible to scan, the left side was scanned. Two individuals 
had too large feet for the HRpQCT carbon fiber shell and were not scanned at the 
tibia. Four individuals had either too large wrists for the carbon fiber shell or the 
scan was of poor quality at the wrist and data were excluded from analysis. For each 
scan, a scout view was performed to define the measurement region using a 
threshold of 9.5 mm and 22.5 mm for the radius and tibia, respectively. At each 
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skeletal site 110 images were obtained. All images were graded based on 
suggestions from the Manufacturer from 1 to 5 (1 = best, 5 = worst) and all images 
graded 4 or 5 required a rescan. All scans were analyzed with software provided by 
Scanco Medical (Switzerland). The analyses performed were standard evaluation 
providing structural and density parameters, finite element analysis with providing 
stiffness, maximum load, and deformation parameters, and cortical evaluation which 
provides cortical porosity parameters. 
All scans and all evaluations were performed by J Starup-Linde. 18 scans were 
performed in duplicates (17 at the radius and 16 at the tibia) to assess the CV of the 
scan. The first scan was performed and afterwards the carbon fiber shell was 
removed and repositioned. The CV was 0.7 % and 1 % for the tibia and radius scans, 
respectively.   
 
4.55 EVALUATION OF VERTEBRAL FRACTURE (PAPER 6) 
Vertebral fractures were evaluated by Vertebral Fracture Assessment (VFA), an 
analysis from the Hologic Discovery DXA scan on patients from the center at 
Aarhus University Hospital and by x-ray of thoracic and lumbar spine at the Aalborg 
University Hospital center (164). Fractures were defined as a 20 % reduction in 
vertebral height and graded by the Genant Classification (165). All x-rays were 
analyzed by a radiologist. If the VFA was suspected of a fracture an x-ray was 
performed to confirm the diagnosis.   
 
4.56 REGISTRY DATA (PAPER 6) 
From the Danish National Hospital Discharge Register all diagnoses of the 197 
patients with diabetes were extracted in the time period 01-01 1977- 10-03 2015. We 
obtained data on fractures in the period 1977-2015 the ICD-10 codes (ICD-10 codes: 
S02.0–S02.9, S07.0–S07.9, S12.0–S12.9, S22.0–S22.9, S32.0–S32.8, S42.0–S42.9, 
S52.0–S52.9, S62.0–S62.9, S72.0–S72.9, S82.0–S82.9, S92.0–S92.9) and the ICD 8 
codes (800–808.09, 808.11–808.19, 808.91–816.09, 816.19, 816.99–820.12, 
820.18–820.92, 820.98–821.22, 821.28–821.32, 821.38–821.92, 821.98–824.03, 
824.08–824.13, 824.18–824.93, 824.98–825.99, 826.01–826.19, 826.99–829.99). 
Fractures were grouped into those prior to the examination and incident fractures 
subsequent to the examination. Furthermore, major osteoporotic fractures were 
defined as fracture at hip, spine, shoulder or forearm. Charlson comorbidity index 
was obtained using codes previously described in detail by Christensen et al. (166). 
Previous hypoglycemic events, and falls were investigated using the ICD 10 codes 
E160, E161, and E162 and ICD 8 codes 25101 and 25100 and W codes, 
respectively. Previous measured biochemical parameters were obtained from the 
hospitals in Central Region of Denmark (2008- ) and the Northern Region of 
Denmark (2006- ). The previously measured biochemical parameters were evaluated 
in a clinical context; therefore some specific parameters are only available for a 
subgroup of patients.  
 
54 
 
4.57 POWER CALCULATION 
The study size was determined on a power calculation based on BMD measurements 
from the previous studies by Shu et al . (101) and Vestergaard. (11). Vestergaard. 
found a difference in Z-score of 0.63 between patients with T1D and T2D and Shu et 
al. reported a standard deviation of 1.4, therefore we used an SD of 1. Setting 2α to 
5 % and β to 10 % we estimated that 51 patients were needed in each group to find 
differences in BMD and therefore we rounded up to 100 participants in each. 
  
4.58 STATISTICS 
Descriptive statistics was used to investigate associations between structural 
parameters, biochemical parameters, and patient characteristics. STATA 8 was used 
to perform the statistics. Mean values of previously measured biochemical 
parameters and the time span between these parameters were calculated. Unpaired t-
test was performed to test for differences between patients with T1D and T2D. 
Linear regression solely adjusted by diabetes type was performed to determine 
associations between characteristics, biochemical parameters, and structural scans. 
To assess differences based on binary variables diabetes type stratified unpaired t-
tests were performed. Multiple linear regression models were performed stratified 
by diabetes type. Assumptions were checked before performing the linear 
regressions. A composite fracture endpoint combining vertebral fractures and 
incident fractures was constructed. To assess the association between the composite 
fracture endpoint and structural and biochemical markers of bone, unadjusted and 
adjusted unconditional logistic regression stratified by diabetes type was performed.  
 
4.6 THE INTERVENTIONAL STUDY (PAPER 7) 
The interventional study was registered at ClinicalTrials.gov (NCT02213276). The 
study was approved by the Danish Data Protection Agency and the Ethics 
Committee of the Central Denmark Region. The clinical study was conducted 
according to the Helsinki declaration.  
 
4.61 DESIGN AND PARTICIPANTS 
The study was an experimental cross over trial, in which participants underwent an 
OGTT and an isoglycemic intravenous glucose infusion (IIGI) on separate days 
divided by at least one week. Twelve healthy Caucasian males were recruited by 
postings at Aarhus University and online at forsøgsperson.dk. Participants gave 
informed voluntary consent to participation in the study. To be eligible for inclusion 
the participants had to be between 20 and 50 years of age, be otherwise healthy, and 
receive no pharmaceutical products. Before each experimental day, participants were 
asked to refrain from exercise, smoking, and taking vitamin supplements for one 
day. They were given a standardized meal between 17 and 23 o’clock. Hereafter 
they were asked to fast (water allowed) from 23 o’clock until they arrived for the 
experiment the next morning. They were asked to arrive by car or bus. At arrival 
participants filled in questionnaires about eating and exercise habits. 
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4.62 ORAL GLUCOSE TOLERANCE TEST 
An OGTT was performed on the first experimental day. The participants consumed 
an oral glucose solution consisting of 82.5 g of glucose monohydrate (equal to 75 g 
of glucose), 225 ml of water and 225 mg of benzoic acid. Upon arrival, a peripheral 
intravenous catheter was placed a cubital vein. Blood samples were collected at -15, 
-10, 0, 15, 30, 60, 120, and 180 minutes from ingestion of the glucose solution. P-
glucose was measured at -15, -10 minutes from ingestion and every 5 minutes for 
the first 2 hours and every 15 minutes for the last hour using an Accu-Chek inform 
II apparatus (Roche Diagnostics, Basel, Switzerland).   
 
4.63 ISOGLYCEMIC INTRAVENOUS GLUCOSE INFUSION 
An IIGI was performed on the second experimental day. A 20% glucose solution 
was intravenously infused. The infusion rate was adjusted according to the p-glucose 
levels measured on the first experimental day to reproduce the glucose curve 
observed at the OGTT. Upon arrival, a peripheral intravenous catheter was placed in 
each of the participant’s cubital veins; one was used for glucose solution infusion 
and one was used for collecting blood samples.  Blood samples and p-glucose were 
sampled at the same time points as for the OGTT.  
 
4.64 BLOOD SAMPLES 
A fasting blood sample was drawn at the first experimental day obtaining plasma 
samples for HbA1c, TSH, and 25 OHD vitamin, calcium, PTH, triglyceride, total 
cholesterol, LDL-cholesterol and HDL-cholesterol. Other samples were divided into 
aliquots and stored at -80 °C. 
S-CTX and s-P1NP were measured by immunometric sandwich assays using the 
COBAS 6000 E at the time points 0, 60, 120, and 180 minutes. The coefficients of 
variation for the analyses were 5 % and 3.7 %. Analyses were carried out at the 
Department of Clinical Biochemistry at Aarhus University Hospital, an ISO 15189 
certified laboratory. 
 
4.65 STATISTICAL ANALYSIS 
Statistical analysis was carried out in a STATA 13 package. Repeated measures 
ANOVA was used for analysis. Normality of data was checked by q-q-plots. The 
compound symmetry assumption was not violated when examining the pooled 
within-subject covariance. To validate the results three conservative F-tests were 
performed. 
 
4.7 METHODOLOGICAL CONSIDERATIONS 
4.71 METHODLOGICAL CONSIDERATIONS IN PAPER 1-3 
The papers 1, 2, and 3 are based on literature searches. To conduct a literature search 
it is important to have described a clear aim, which leads to a selection of search 
terms and use of eligibility criteria for the inclusion of records. The quality of the 
review, meta-analysis, and systematic review is determined by the quality of the 
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literature search. The quality of the literature search is based on the search terms 
used. The search terms may neither be too narrow (missing relevant papers) or too 
broad (too many papers resulting in a huge workload). In the papers 1-3 the 
literature searches conducted was quite broad resulting in many hits of which 
relatively few were relevant, however this minimizes the chance of missing 
important records. Furthermore, when deciding whether a record is eligible, papers 
may be excluded wrongfully. One reviewer J. Starup-Linde decided for the 
eligibility of the records which gives consistency between the papers 1-3, however it 
increases the risk of a systematic error. Under optimal circumstances two reviewers 
should have decided whether the records were eligible for inclusion. Furthermore, 
when conducting a literature search, using indexed search terms, there is a risk of 
missing relevant papers due to incorrect indexing or papers so recent, that they have 
not been indexed. For the papers 1 and 2 only observational records were included. 
Due to the cross-sectional design of most of the records both the narrative review 
and the meta-analysis cannot conclude on causality and only find associations. For 
the paper 3 both observational records and randomized controlled trial records were 
included. However, when examining bone turnover markers in patients with diabetes 
versus subjects without diabetes it is impossible to randomize to diabetes status. To 
evaluate on the effects of antidiabetic medication on bone turnover markers as in 
paper 3, records of a double blinded randomized controlled design is optimal. 
A study (167)  in the systematic review, paper 3, reported on patients with T2D in 
hemodialysis and controls in hemodialysis and reported no association between 
fracture and PTH and BMD. It is a limitation, however it did not change the general 
interpretation or conclusions of the paper. 
 
4.711 THE META-ANALYSIS (PAPER 2)  
The data extraction from the records is an important step in conducting the meta-
analysis. If the data is incorrectly extracted it will lead to errors in the results. To 
avoid this, data extraction was performed independently by two reviewers J. Starup-
Linde and S.A. Eriksen. The strengths of the meta-analysis were the large number of 
studies included and that the comparison between patients with diabetes and controls 
was made in the individual study. This generates a high statistical power compared 
to a single study. A drawback to the meta-analysis is the lack of information on 
antidiabetic treatment, statin use, and antiosteoporotic treatment and inconsistencies 
between studies. As patients with diabetes may differ in characteristics as well as 
renal function, fasting status at the sample collection, 25 OH vitamin D and PTH 
status it can be difficult to pool the studies, however this should not limit the value 
of results as the comparison to controls was performed in each study. Neither renal 
function nor fasting status is likely to affect the results, as fasting status did not 
determine the levels of bone turnover markers in the meta-regression and only one 
study reported results from patients with renal disease (168).  
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4.712 THE METHODOLOGICAL STUDY ON THE EFFECTS OF 
GLUCOSE ADDED TO SERUM ON THE MEASUREMENTS OF BONE 
TURNOVER MARKERS (PAPER 2) 
This investigation was conducted on serum samples from healthy individuals and 
thereby it cannot conclude on in vivo conditions or on patients with diabetes. The 
study is limited to examining the analysis of the bone turnover markers and resolve 
whether it changes by the addition of glucose. Using a control without glucose 
addition and following the bone turnover markers over time are strengths to the 
investigation. 
 
4.72 METHODLOGICAL CONSIDERATIONS IN PAPER 4 
The case control study in paper 4 was a retrospective case-control study and thus 
causality cannot be assessed. The study relies on the validity of the diagnoses of 
diabetes and fracture and the registration of the diagnoses. In general the validity of 
the diagnoses is high in the Danish registries. The Danish registers cover the entire 
Danish population; however the study was restricted to inpatient and outpatient 
diagnoses from the hospitals and therefore not patients treated only by the general 
practitioner. Furthermore, it was not possible to examine whether medication was 
actually taken although registered medication has been bought. However, non-
compliance may only be a minor problem as most diabetes associated therapies are 
taken on a regular basis. In an attempt to adjust for falls; fall diagnoses were 
collected but only 5 of the 2,627 patients had a prior diagnosis of tendency to falls, 
and none of these experienced a fracture and it was not included in the analysis. The 
study may be restricted by the limited number of subjects which biochemical 
markers and pharmaceutical use were available for; this may lead to selection bias as 
it is unknown whether the total population of patients with diabetes shares the same 
characteristics as these 2,627 patients with diabetes. It was not possible to adjust for 
important life style factors; BMI data was missing for most patients, but was 
previously shown not to be significantly associated with LDL-cholesterol (169) and 
smoking and alcohol use was based on proxy variables.  
The strength of a case control design is that few outcomes are needed to determine 
an association as the selection is made on the outcome unlike cohort studies where 
the selection is based on the exposure. Furthermore, the case control study is 
hypothesis generating for future studies.   
 
4.73 METHODOLOGICAL CONSIDERATIONS IN PAPER 5 AND 6  
4.731 THE DESIGN 
The strengths of the cross-sectional study (paper 5 and 6) was the large sample size 
of well characterized relatively dysregulated diabetes patient, the number of 
fractures, and the option to adjust the finding for relevant factors that may influence 
results. In general a cross-sectional study may define many research questions and 
collect large amounts of information and be hypothesis generating for future studies. 
Another advantage is that the information can be collected within a short time frame 
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with multiple outcomes. However, the cross-sectional study was restricted by its 
own design as it was not able to determine causality. Another weakness to the cross-
sectional study is that if the trait under investigation is rare in the general population 
a large sample is needed; however diabetes is a prevalent disease and the patients 
were recruited from outpatient clinics at the University Hospitals that have a large 
patient flow. The recruitment from outpatient clinics may lead to selection bias as 
these represent a group of diabetes patients unlike those followed solely at the 
general practitioners. Furthermore, the cross-sectional study is sensitive to recall 
bias and misclassification. All patients were interviewed for medical history, 
medication use by a trained MD, J. Starup-Linde, and secondly by the extracting 
medical files which increase the reliability of the collected data.  
 
4.732 BIOCHEMICAL BONE MARKERS 
All biochemical bone markers were analyzed by trained staff at the same laboratory 
(Department of Clinical Biochemistry, Aalborg University Hospital). A limitation 
was that the blood samples were taken under non-fasting conditions. It is known that 
feeding decrease s-CTX, whereas s-OC and p-FGF-23 are known not to be affected 
(139, 170), thus the interpretation of p-CTX may be difficult. However, the same 
conditions applied to all participants and p-CTX was associated with p-glucose in 
the same manner as p-P1NP and p-OC. Furthermore, fasting status did not relate to 
measured s-CTX or s-OC values in the meta-analysis (114). It is difficult to obtain a 
fasting condition in diabetes as it is characterized by an increased fasting p-glucose 
(47). A limitation to the bone turnover markers is the missing s-PTH, s-BAP, s-
calcium, and s-phosphate values. These may further explain the bone status in 
patients with diabetes.  
The comparison between bone markers measured in the cross-sectional study and 
reference ranges should be interpreted with caution as we cannot be sure that the 
laboratories measure the same levels of bone turnover markers. The manufacturer 
are not obliged to provide information on possible new measurement levels in the 
kits used for bone turnover markers, thus it may be difficult to compare to previous 
reference ranges. 
 
4.733 DXA  
DXA images were obtained by trained technicians. Quality control of all DXA-
scanners was performed on a daily basis using phantom scans. Due to the usage of 
four different DXA-scanners that were significantly different the BMD measures 
were recalculated based on the quality control scans of a phantom (described in 
section 4.53) so the DXA results were comparable between the DXA-scanners. 
When vertebral fractures were observed the fractured vertebrae were not included in 
the BMD as it may lead to overestimation. As patients with diabetes may have more 
aortic calcification it may overestimate the lumbar spine BMD. 
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4.734 HRPQCT 
To ensure comparability all HRpQCT-scans were performed and all images 
evaluated by J. Starup-Linde. Patients with diabetes have heterogeneous bones; 
where some have large bones and other small bones and in few cases it was not 
possible to fit the cast to the extremity. The accuracy and reproducibility of the 
scans depend on patient positioning. The precision CV performed for a subgroup is 
acceptable (described in section 4.54). Motion artifacts could not be avoided 
completely although the scanner include a motion detector and the scan could be 
repeated. To avoid drift of the X-ray source routine quality control scans were 
performed on routine basis.  
 
4.735 VERTEBRAL FRACTURES 
All VFA and X-ray images were obtained by trained staff. To ensure the diagnosis 
of a fracture it had to be confirmed by a radiologist. The collection of vertebral 
fracture may be limited by the two different methods; VFA and X-ray. VFA 
detected a vertebral fracture in 2 % of the patients whereas X-ray detected a fracture 
in 28 % of the patients. Studies have concluded that X-ray and VFA are comparable 
(171, 172), although VFA had a reduced sensitivity for mild fractures (based on the 
Genant classification) and could not asses all vertebral levels (171, 172).  
 
4.734 REGISTRY DATA 
Information on diagnoses was collected from the Danish National Hospital 
Discharge Register. This gives the opportunity to both validate previous diagnoses 
and to do a longitudinal follow up on specific endpoints- in this case fracture. The 
Danish registries are an easy method to collect hard endpoints, however they are 
susceptible to misclassification and confounding.  
 
4.74 METHODOLOGICAL CONSIDERATIONS IN PAPER 7 
The experimental study examined bone turnover markers in the same individuals at 
OGTT and IIGI and thus avoided confounding by differences in characteristics. It 
may only be generalized to healthy young men as it was the group examined. The 
examination was standardized and all individuals were asked to refrain from 
exercise, smoking, and intake of vitamin supplements the day before and were given 
a standardized meal the night before, thus individual lifestyle habits are unlikely to 
influence the study. It is, however, limited by the lack of a control examination 
where the decrease of s-CTX is investigated over time. Furthermore, it is uncertain 
which gastro-intestinal hormones, may affect bone turnover as these are not 
examined. 
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5. SUMMARY OF RESULTS 
5.1 PAPER 1: “DIABETES, BIOCHEMICAL MARKERS OF BONE 
TURNOVER, DIABETES CONTROL, AND BONE.”  
A qualitative analysis investigating bone turnover in patients with T1D and T2D in 
comparison with normal controls was performed (115). Section 1.7 describes the 
bone turnover markers in further details, while this section and sections 5.2 and 5.3 
summarize the most relevant information on bone turnover markers for patients with 
diabetes. Figure 11 summarize the analysis. In general s-OC and s-CTX seemed to 
be lower in both patients with T1D and T2D compared to controls, whereas s-
sclerostin and u-NTX seemed to be increased and s-P1NP and s-TRAP seemed to be 
decreased in patients with T2D. S-IGF-1 and s-OPG seemed to be decreased in 
patients with T1D compared to controls. In comparison to controls; patients with 
T1D seemed to have unchanged s-calcium, u-calcium, s-PTH, s-alkaline 
phosphatase, s-BAP, s-TRAP, s-NTX, and u-crosslaps. In comparison to controls 
patients with T2D seemed to have unchanged s-calcium, u-calcium, s-PTH, s-
alkaline phosphatase, s-BAP, s-procollagen type 1 carboxyl terminal propeptide 
(P1CP), and s-CICP. Bone turnover markers did not seem to differ between the 
diabetes types. From fig. 10 it could be speculated that a difference in s-sclerostin 
was present between patients with T1D and T2D as s-sclerostin was not different 
between patients with T1D and controls in the study by Gennari et al. (37). A need 
for further investigations into sclerostin was this present and addressed in my 
studies. The narrative review pointed at heterogeneity in the biochemical variables, 
which is explored further below in a formal meta-analysis. 
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Figure 11. Adapted from Starup-Linde et al. 2013 with permission (115). Overview 
of the bone turnover markers which are likely to differ between patients with 
diabetes and controls. ↑indicate raised marker ↓ indicate lowered marker. Blue and 
green circles indicate markers that appear decreased and increased in patients with 
diabetes, respectively.  
 
5.2 PAPER 2: ”BIOCHEMICAL MARKERS OF BONE TURNOVER 
IN DIABETES PATIENTS- A META-ANALYSIS, AND A 
METHODOLOGICAL STUDY ON THE EFFECTS OG GLUCOSE 
ON BONE MARKERS.” 
5.21 THE META-ANALYSIS 
A quantitative meta-analysis of bone turnover markers in patients with diabetes 
compared to non-diabetes subjects was performed. 22 studies were included in the 
meta-analysis and 18 studies also in the meta-regression. The NOS score ranged 
between 5 and 9 and thus the quality of the studies was fair. Heterogeneity was 
present in participant characteristics and use of methods between the studies. The 
study sizes were also heterogeneous with diabetes populations as small as 25 and at 
the most 890. The control group sizes varied in the same manner from 15 to 1,058. 
Twelve different methods were used to determine OC and five different methods to 
determine CTX. A description of the studies included in the pooled analysis is 
available in paper 2 (114).  
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The evaluated bone markers displayed heterogeneity among the studies; however no 
publication bias was present. In the pooled analysis s-25 OH vitamin D was lower in 
patients with diabetes compared to controls (-11.14 nmol/l 95% CI: -20.13 ; -2.15), 
whereas s-phosphate was increased in patients with diabetes (0.13 mg/dl 95% CI: 
0.11 ; 0.16). Both s-OC (-1.15 ng/ml 95% CI: -1.78 ; -0.52) and s-CTX (-0.14 ng/ml 
95% CI: -0.22 ; -0.05) was lower among patients with diabetes and u-NTX 
borderline significantly increased (15.44 nM/mM creatinine 95% CI: -0.74 ; 31.62), 
whereas no difference was present regarding s-PTH, s-calcium, s-BAP, s-CICP, and 
s-DPD. The results of s-OC and s-CTX are displayed in Figure 12 and 13.  
Subgroup analysis by patients with T1D and T2D revealed decreased s-25 OH 
vitamin D and s-OC in patients with T1D and increased s-phosphate in patients with 
T2D compared to controls. S-OC was borderline significantly lower in patients with 
T2D (P = 0.06). S-OC was decreased independent of gender and menopausal status, 
whereas s-CTX was decreased in male and premenopausal patients with diabetes, 
but not in postmenopausal women with diabetes. 
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Figure 12. Pooled analysis of differences in osteocalcin levels between patients with 
diabetes and controls. Analysis performed by random effects model. With permission 
from Starup-Linde et al. (114). 
 
 
Figure 13. Pooled analysis of differences in CTX levels between patients with 
diabetes and controls. Analysis performed by random effects model. With permission 
from Starup-Linde et al. (114). 
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5.211 META-REGRESSION 
A meta-regression on possible determinants of bone turnover markers was 
performed as a sensitivity analysis to the meta-analysis. The meta-regression 
analyses was restricted to patients with diabetes and revealed that neither, age, 
gender, BMI, diabetes type, diabetes duration, HbA1c, fasting status nor creatinine 
levels determined s-CTX or s-OC levels. However, when stratified by diabetes type 
age and diabetes duration was positive determinants of s-OC in patients with T1D. 
Also, HbA1c was positively associated with s-BAP levels.  
 
5.22 THE METHODOLOTGICAL STUDY ON THE EFFECTS OF 
GLUCOSE ADDED TO SERUM ON THE MEASUREMENTS OF BONE 
TURNOVER MARKERS 
The narrative review and meta-analysis raised the question of glucose per se could 
interfere with the measurements of say P1NP and CTX e.g. through glycation and 
thus altered presentation of the epitopes, perhaps leading to these failing to be 
recognized by the assay. This was explored further in a methodological study. 
Addition of glucose to serum did not change the bone turnover markers s-P1NP, s-
OC, and s-CTX neither by the dose of glucose or the increasing incubation period. 
The results are presented in Table 3. 
 
Regression 
Coefficient 
P1NP Osteocalcin CTX 
Time -.416 (0.432) -,386 (0.348) -0.006 (0.013) 
Addition of 
glucose  
0.000 (0.065) 0.006 (0.053) 0.000 (0.002) 
R
2
 0.031 0.041 0.007 
Table 3. Multiple linear regression analysis by time and dose of added glucose for 
P1NP, osteocalcin, and CTX. 
Values are regression coefficients (standard error). Bold indicates significance 
(P<0.05). R
2
 prediction power for the model including time and addition of glucose.  
 
 
5.3 PAPER 3: “BIOCHEMICAL BONE TURNOVER MARKERS IN 
DIABETES MELLITUS – A SYSTEMATIC REVIEW.” 
From the studies above it was concluded that methodological issues related to the 
glucose levels could not explain the decreases in s-OC and s-CTX, and that large 
methodological variations were present and that bone turnover markers were likely 
to be lower in diabetes than in controls. However, the decrease varied between the 
markers and even within markers from the same molecule (CTX and NTX) 
variations were seen. This was further explored and related to among other fracture 
risk in a systematic review. 
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The forty seven studies included were and comprised 1 meta-analysis, 29 cross-
sectional studies, 4 longitudinal studies, and 13 randomized controlled trials. The 
study sizes were heterogeneous and varied from 24 (173) to 1,605 (132). 
The included studies are presented in paper 3. The diabetes ascertainment used by 
the studies was in general valid and the studies reported fasting bone turnover 
marker values with the exception of five studies. Individuals with kidney disease 
were in general excluded, although a single study reported on hemodialysis patients 
(167). Based on the studies bone markers still seemed to be decreased in both 
patients with T1D and T2D, however, s-BAP tends to be increased. Potential 
fracture predictors were evaluated and decreased levels of s-OC (126), s-IGF-1 
(126-128), increased levels of s-sclerostin (127, 129) and an imbalance in bone 
turnover by high s-CTX and low s-P1NP (130) were all associated with prevalent 
fractures. 
 
5.4 PAPER 4: “LOW-DENSITY LIPOPROTEIN CHOLESTEROL IS 
ASSOCIATED WITH FRACTURE RISK IN DIABETES PATIENTS – 
A NESTED CASE-CONTROL STUDY.” 
5.4.1 CHARACTERISTICS  
Prior studies on fracture risk in diabetes have not explored systematically the full 
range of potential confounders for fracture risk. Some potential confounders such as 
atherosclerosis and hypertension may be associated with diabetes, and smoking, 
which is a risk factor for atherosclerosis is also a risk factor for fractures. 
Atherosclerosis may be treated with statins, which per se have also been associated 
with a decreased risk of fractures. I therefore conducted a nested case-control study 
in order to investigate fracture risk in diabetes and the potential impact of 
confounders. 
2,627 diabetes mellitus patients were included in the study. 175 had a fracture after 
diabetes diagnosis. Table 4 displays patient characteristics. Patients with a fracture 
were significantly older, had significantly longer diabetes duration, and were more 
prone to have a history of previous fracture, and an alcohol-related diagnosis. 
Gender and diabetes complications were not significantly different between cases 
and controls. 
The unadjusted and the adjusted analysis are displayed in Table 5. Age (1.02 ; 95CI: 
1.01-1.03), diabetes duration (1.04 ; 95CI: 1.01-1.07), previous fracture (2.05 ; 
95CI: 1.48-2.82), an alcohol related diagnosis (3.04 ; 95CI: 1.95-4.73), and 
neuropathy (1.92 ; 95CI: 1.11-3.32) increased risk of fracture in the unadjusted 
analysis. In the adjusted analysis age (1.02 ; 95CI: 1.01-1.04), diabetes duration 
(1.06 ; 95CI: 1.02-1.09), history of a previous fracture (2.19 ; 95CI: 1.55-3.10), and 
an alcohol related diagnosis (2.97 ; 95CI: 1.78-4.98) remained significant. 
Furthermore, total cholesterol increased the risk (2.53 ; 95CI: 1.22-5.25) and LDL-
cholesterol (0.34 ; 95CI: 0.16-0.74) decreased risk of fracture significantly. LDL-
cholesterol was still significantly associated with a decrease in fracture risk in the 
specific analysis for patients with T2D and significance levels did not change.   
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 Fracture after diabetes 
diagnosis (n = 175) (95% 
CI) 
No fracture after 
diabetes diagnosis (n = 
2,452) (95% CI) 
Characteristic   
Age /years * 65.9 (63.8 ; 68.0) 62.5 (61.9 ; 63.0) 
Diabetes duration /years *
†
  6.7 (6.1 ; 7.3) 5.8 (5.6 ; 6.0) 
Sex male %  48.6 (41.1 ; 56.0) 54.2 (52.2 ;  56.2) 
Previous fracture % *
†
 36.6 (29.4 ; 43.8) 22.0 (20.3 ; 23.6) 
Alcohol-related diagnosis 
% *
†
 
15.4 (10.0 ; 20.8) 5.7 (4.8 ; 6.6) 
T2D %  
†
 85.2 (78.6 ; 91.8) 89.7 (88.3 ; 91.1) 
Neuropathy % 
†
 9.1 (4.8 ; 13.5) 5.0 (4.1 ; 5.8) 
Retinopathy %  4.0 (1.1 ; 6.9) 3.3 (2.6 ; 4.1) 
Vascular complications %   11.4 (6.7 ; 16.2) 10.8 (9.6 ; 12.8) 
Biochemical parameters 
(mean ± SE) 
  
Creatinine µmol/l 
†
 85.2 ± 2.4 84.5 ± 0.7 
HbA1c  mmol/mol  53 55 
Total cholesterol mmol/L 
†
 4.4 ± 0.8 4.4 ± 0.2 
HDL mmol/L *
†
 1.4 ± 0.4 1.3 ± 0.1 
LDL mmol/L  
†
 2.2 ± 0.1 2.3 ± 0.1 
Table 4. Baseline characteristics of the 2,627 patients with diabetes. 
* P < 0.05 for difference between patients with diabetes with incident fractures and 
patients with diabetes without incident fractures. 
†
 T-test performed with unequal variances, due to estimation by Bartlett’s test  
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Characteristic Unadjusted odds 
ratio (95 % CI) 
Adjusted odds 
Ratio (95 % CI)
 α
 
Age (years) 1.02 (1.01-1.03)* 1.02 (1.01 ; 
1.04)* 
Diabetes duration (years)  1.04 (1.01-1.07)* 1.06 (1.02 ; 
1.09)* 
Sex male 0.80 (0.59 ;1.08) 0.74 (0.52 ; 1.06) 
Sex male n= 1,663
‡
 0.70 (0.46 0.61 (0.37 ; 1.00) 
Smoker proxy variable  0.75 (0.46 ; 1.23) 0.69 (0.40 ; 1.19) 
Previous fracture   2.05 (1.48 ; 
2.82)* 
2.19 (1.55 ; 
3.10)* 
Alcohol-related diagnosis   3.04 (1.95 ; 
4.73)* 
2.97 (1.78 ; 
4.98)* 
Neuropathy  1.92 (1.11 ; 
3.32)* 
1.69 (0.93 ; 3.07) 
Retinopathy  1.20 (0.55 ; 2.65) 0.95 (0.41 ; 2.20) 
Peripheral artery disease 1.06 (0.65 ; 1.72) 0.73 (0.43 ; 1.24) 
Biochemical parameters   
Creatinine µmol/l 1.00 (1.00-1.00) 1.00 (0.99 ; 1.00) 
HbA1c % 0.89 (0.77-1.02) 0.93 (0.78 ; 1.10) 
Total cholesterol mmol/L  1.10 (0.92-1.30) 2.53 (1.22 ; 
5.25)* 
Total cholesterol mmol/L   n= 1,663
‡
 1.19 (0.96 ; 1.49) 3.68 (1.27 ; 
10.65)* 
HDL mmol/L  1.54 (1.09-2.17)* 0.56 (0.25 ; 1.24) 
LDL mmol/L  0.88 (0.70-1.10) 0.34 (0.16 ; 
0.74)* 
LDL mmol/L   n= 1,663
‡
 0.99  (0.75 ; 1.34) 0.27 (0.09 ; 
0.80)* 
Triglycerides mmol/L 1.03 (0.90-1.18) 0.83 (0.60 ; 1.14) 
Table 5. Unadjusted and adjusted odds ratio for fracture after diagnosis of diabetes 
n = 2,627. Nephropathy cases were excluded from the analysis. 
* P < 0.05, 
α
Adjusted by potassium levels, sodium levels, alanine transaminase 
levels, alkaline phosphatase levels, antipsychotic use, antiepileptic use, 
glucocorticoid use, antihypertensive use, antidepressant use, statin use, previous 
heart failure, antidiabetic use (stratified by type), drugs affecting bone turnover, 
previous acute myocardial infarction, in addition to all variables in the table. 
‡
 Analysis performed after excluding all patients with type 1 diabetes (n=1,663) 
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5.42 LDL AND FRACTURE RISK 
The LDL-cholesterol level was divided by 8-quantiles in patients with T2D. The 
lowest quintile (0-1.53 mmol/l) had a significantly higher risk compared to the other 
quintiles. Compared to the reference of 2.23-2.44 mmol/l higher LDL-cholesterol 
levels had lower fracture risk. The analysis was adjusted by statin use as it may 
influence results. Figure 14 presents the relationship between LDL-cholesterol levels 
and fracture risk in patients with T2D.  
 
Figure 14. Adjusted Odds Ratio with 95 % confidence intervals for fractures in 
patients with type 2 diabetes by LDL-cholesterol level (n=1,663). * P < 0.05 
compared to the reference.  Adjusted by age, diabetes duration, sex, smoker proxy 
variable, previous fracture, alcohol diagnosis, retinopathy, neuropathy, peripheral 
artery disease, AMI, heart failure, alat, alkaline phosphatase, creatinine, HbA1c, 
total cholesterol, HDL cholesterol, triglycerides, sodium, potassium, insulin, 
biguanides, β-cell stimulants, GLP-1 receptor agonists, statins, antihypertensive, 
glucocorticoids, bone affecting drugs, antidepressants, antipsychotics and 
antiepileptics.  
 
5.5 PAPER 5: “ DIFFERENCES IN BIOCHEMICAL BONE 
MARKERS BY DIABETES TYPE AND THE IMPACT OF 
GLUCOSE.” 
5.51 CHARACTERISTICS 
In order to study the impact of turnover markers on bone structural parameters and 
fracture risk, a cross-sectional study was performed. The cross-sectional study is 
covered by paper 5 and paper 6. Paper 5 examines differences in bone turnover 
markers between patients with T1D and T2D. 197 patients with diabetes were 
included distributed with 101 patients with T1D and 96 patients with T2D. Patient 
characteristics are given in Table 6. Patients with T2D had a significantly higher 
BMI and age and lower diabetes duration compared to patients with T1D. Gender, 
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smoking, alcohol consumption, and microvascular complications did not differ 
between the diabetes types. The patients were relatively dysregulated with a mean 
HbA1c of 8.0 % (64.0 mmol/mol) and a mean non-fasting p-glucose of 10.8 mmol/l. 
HbA1c, creatinine, and p-glucose levels were not different between patients with 
T1D and T2D.  
 
5.52 BIOCHEMICAL MARKERS OF BONE TURNOVER 
The biochemical markers of bone turnover and the differences between patients with 
T1D and T2D are presented in Table 6. P-P1NP and p-OC were significantly higher 
in patients with T1D (41.2 ng/ml vs. 35.7 ng/ml and 19.5 ng/ml vs. 15.5 ng/ml, 
respectively), whereas p-CTX and p-ucOC were not different between diabetes 
types. S-RANKL was significantly higher in patients with T1D (62.1 pmol/ml vs. 
44.9 pmol/ml) whereas s-OPG was significantly lower (4.65 pmol/l vs. 5.32 pmol/l) 
in patients with T1D when comparing with patients with T2D. P-FGF-23 (97.3 
RU/ml vs. 113 RU/ml) and p-sclerostin (68.1 pmol/l vs. 73.5 pmol/L) were not 
different between diabetes types.  
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Table 6. Characteristics of the patients with diabetes divided into diabetes types (n 
= 197). 
T1D: Type 1 diabetes, T2D: Type 2 diabetes. P-values for differences between 
diabetes types  in unpaired t-test, Bold indicates statistical significance, 
†
unequal 
variance from Bartletts test and t-test performed with unequal variance 
 
5.53 LINEAR REGRESSION  
To examine association between bone turnover markers and factors that may 
influence bone turnover linear regression analyses were performed. In simple linear 
regression analyses adjusted by diabetes type; non-fasting p-glucose levels were 
related to a significant decrease in p-CTX (β = -4.23), p-P1NP (β = -0.651), p-OC (β 
= -0.244), and p-ucOC (β = -4.23) and an increase in s-OPG (β = 0.135). These 
Variable T1D mean 
(95%CI) (n=101) 
T2D mean 
(95%CI) (n=96) 
P-value 
Characteristics    
Age (years) 60.7 (59.2 ; 62.2) 65.2 (63.6 ; 66.7) <0.001 
Gender (% male) 59.4  64.6  0.457 
BMI (kg/m
2
) 25.8 (25.1 ; 26.6) 30.7 (29.9 ; 31.6) 
(n=95) 
<0.001 
Diabetes duration (years) 24.4 (21.9 ; 26.8) 14.6 (13.1 ; 16.2) <0.001
†
 
Microvascular complications 
(%) 
46.5  45.8  0.922 
Macrovascular complications 
(%) 
3.96  15.6  0.006
†
 
Current smoker (%) 18.8  29.2  0.089 
Alcohol use (units/week) 6.86 (5.36 ; 8.36) 4.85 (3.51 ; 6.20) 0.050 
Statin use (%) 60.4  79.2  0.0041 
Biochemical parameters    
CTX (ng/l) 217 (197 ; 236) 189 (166 ; 211) 0.062 
Osteocalcin (ng/ml) 19.5 (18.3 ; 20.7) 15.5 (14.3 ; 16.8) <0.001 
Undercarboxylated osteocalcin 
(ng/ml) 
4.99 (3.08 ; 6.90) 6.38 (3.50 ; 9.2) 0.426 
P1NP (ng/ml) 41.2 (38.3 ; 44.1) 35.7 (32.7 ; 38.7) 0.010 
FGF-23 (RU/ml) 97.3 (78.6 ; 116) 113 (99.3 ; 126) 0.185
†
 
Sclerostin (pmol/l) 68.1 (62.1 ; 74.2) 73.5 (66.0 ; 81.0) 0.269 
RANKL (pmol/l) 0.0621 (0.0489 ; 
0.0753) 
0.0449 (0.0342 ; 
0.0557) 
0.0471
†
 
OPG (pmol/l) 4.65 (4.22 ; 5.08) 5.32 (4.91 ; 5.73) 0.0277 
Creatinine (mmol/l) 74.9 (71.7 ; 78.1) 76.6 (72.8 ; 80.4) 0.493 
25 OHD vitamin (nmol/l) 75.1 (68.6 ; 81.6) 64.5 (58.3 ; 70.6) 0.019 
HbA1c (mmol/mol) 64.5 (62.7 ; 66.4) 63.4 (61.4 ; 65.3) 0.378 
Mean HbA1c of previous 5.9 
years (mmol/mol) 
66.3 (64.7 ; 68.0) 64.4 (62.8 ; 66.0) 0.102 
Glucose (mmol/l) 10.7 (9.74 ; 11.6) 10.9 (10.1 ; 11.6) 0.744
β
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associations are presented in Figure 15. HbA1c was significantly associated with p-
OC (β = -0.112), but not with p-P1NP (P =0.058), p-CTX (P = 0.361), p-ucOC (P = 
0.458) or s-OPG (P = 0.507). The associations between HbA1c and bone turnover 
markers are illustrated in Figure 16. In unadjusted analysis LDL-cholesterol levels 
were significantly associated with p-P1NP (β = 5.77) and p-OC (β = 1.75), however 
this was not present when adjusting by diabetes type.  
 
 
Figure 15. The unadjusted association between non-fasting glucose levels and bone 
turnover marker levels in patients with diabetes (n = 197). 
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Figure 16. Unadjusted association between HbA1c and bone turnover marker levels 
in patients with diabetes (n = 197). 
 
5.54 MULTIPLE LINEAR REGRESSION 
Table 7 present the adjusted association between biochemical markers of bone and 
non-fasting p-glucose. In the adjusted multiple linear regression non-fasting p-
glucose was significantly negatively associated with p-CTX (β = -4.31), p-P1NP (β 
= -0.660), p-OC (β = -0.227), and p-ucOC (β = -0.246) and positively associated 
with s-OPG (β = 0.136). HbA1c was still significantly associated with p-OC in the 
multiple linear regression (β = -0.105). When stratifying by diabetes type non-
fasting p-glucose was significantly negatively associated with p-CTX (β = -5.49) 
and p-P1NP (β = -0.738) and significantly positively associated with s-OPG (β = 
0.117) in patients with T1D. In patients with T2D non-fasting p-glucose was 
significantly associated with s-OPG (β = 0.159).  
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Variable Glucose (mmol/l) (95 % CI) 
CTX (ng/l) * -4.31 (-7.55 ; -1.07) 
P1NP (ng/ml)
 †
 -0.660 (-1.11 ; -0.208)
 
 
Osteocalcin (ng/ml)
 †
 -0.227 (-0.405 ; -0.0489) 
Undercarboxylated osteocalcin (ng/ml)
‡
 -0.426 (-0.825 ; -0.0264) 
OPG (pmol/l)
 ¥
 0.136 (0.0725 ; 0.199) 
Table 7. Multiple linear regression of bone turnover markers and the association 
with non-fasting glucose (n=197).  
Bold indicates statistical significance 
* Adjusted by age, gender, BMI, diabetes type, microvascular disease, alcohol use, 
HDL-cholesterol, and creatinine. 
†
 Adjusted by age, gender, BMI, diabetes type, alcohol use, HDL-cholesterol, and 
creatinine. 
‡
 Adjusted by age, gender, BMI, diabetes type, microvascular disease, and 
creatinine. 
¥
Adjusted by age, gender, BMI, and diabetes type.  
 
5.6 PAPER 6: “BONE STRUCTURE AND PREDICTORS OF 
FRACTURE IN TYPE 1 AND TYPE 2 DIABETES.” 
5.61 CHARACTERISTICS 
Paper 6 investigated differences in bone structure between patients with T1D and 
T2D and associations with fractures. 101 patients with T1D and 96 patients with 
T2D were included. Table 6 presents characteristics of the included patients. The 
Charlson Comorbidity Index was lower in patients with T1D (0.317 points vs. 0.875 
points) compared to patients with T2D; however more patients with T1D had 
experienced a previous hypoglycemic event (31.7 % vs. 2.1 %). No difference was 
observed between patients with T1D and T2D when considering the number of 
previous fractures, previous major osteoporotic fractures, prevalent vertebral 
fractures assessed by VFA or x-ray and incident fracture. The characteristics of the 
population are further described in section 5.51. 
 
5.62 STRUCTURAL PARAMETERS 
Table 8 presents data on the structural parameters by diabetes type. DXA T-scores at 
the spine, hip, and femur (-0.580 vs. 0.123, -0.925 vs. -0.261, and -1.07 vs. -0.669) 
were lower in patients with T1D compared to patients with T2D. No difference was 
present at the forearm BMD. Structural and density parameters and cortical porosity 
measured by HRpQCT was not different between patients with T1D and T2D. The 
tibia and radius cortical pore size and the standard deviation of the pore size were 
increased in patients with T1D compared to patients with T2D.  Furthermore, 
cortical pore volume at the radius was decreased in patients with T1D compared to 
patients with T2D. The finite element analysis revealed increased tissue stiffness in 
patients with T2D at the tibia. In multiple linear regressions the hip T-score and tibia  
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Table 8. Differences in structural bone measurements by diabetes type (n=196). 
T1D: Type 1 diabetes, T2D: Type 2 diabetes P-value for difference between T1D 
and T2D in unpaired t-test, Bold indicate statistical significance, 
†
unequal variance 
from Bartletts test and t-test performed with unequal variance * Two patients with 
type 2 diabetes were not scanned at the hip and femur due to prosthesis. 
 
tissue stiffness remained significantly increased in patients with T2D compared to 
patients with T1D whereas no other structural parameters differed. Mean HbA1c of 
the previous 5.9 years was not associated with aBMD at the hip or spine and vBMD 
of the tibia and radius in either patients with T1D or T2D. 
 
 
5.63 VERTEBRAL FRACTURES 
11 patients experienced an incident fracture subsequent to inclusion in the study (5 forearm 
fractures, 2 tibia  
fractures, 2 fractures of the humerus, 1 fracture of a metacarpal bone, and 1 with multiple 
fractures of spine, clavicle, and rib).  6 fractures were in patients with T1D and 5 
fractures were in patients with T2D. 15 patients with T1D and 8 patients with T2D 
presented with a vertebral fracture at examination. The unadjusted logistic 
regression revealed that fracture was associated with diabetes duration (OR=1.04), 
previous major osteoporotic fracture (OR = 4.47), increasing hip T-score 
(OR=0.498), p-25 OHD vitamin (OR= 1.02), vitamin D supplementation (OR= 
4.08), p-sclerostin (OR= 0.974), and p-sclerostin divided by tertiles (OR= 0.471) in 
patients with T1D. P-sclerostin was also significantly associated with fracture risk in 
the multivariate analysis (OR = 0.413) in patients with T1D. Figure 17 presents the 
association of p-sclerostin and fracture in patients with T1D. The strongest 
association was observed within the third tertile (OR = 0.188) of p-sclerostin 
DXA parameters T1D mean (95%CI) 
(n=101) 
T2D mean 
(95%CI) (n=96) 
P- 
value 
Hip T-score* -0.925 (-1.15 ; -
0.703) 
-0.261 (-0.505 ; -
0.0164) 
<0.001 
Femur T-score* -1.07 (-1.29 ; -
0.839) 
-0.669 (-0.931 ; -
0.407) 
0.024 
Spine T-score -0.580   (-0.863 ; -
0.297) 
0.123 (-0.232 ; 
0.478) 
0.002 
Total forearm BMD 0.556 (0.536 ; 
0.575) 
0.578 (0.560 ; 
0.596) 
0.102 
HRpQCT Tibia    
vBMD (mg HA/cm
3
) 287 (272 ; 302) 298 (285 ; 309) 0.253 
Cortical porosity (%) 7.29 (6.57 ; 8.01) 7.02 (6.50 ; 7.55) 0.540 
Tissue Stifness (kN/mm) 236 (218 ; 254) 261 (244 ; 278) 0.046 
Failure load (N·10
7
)
±
 3.52 ± 3.45 2.71 ± 2.90 0.437 
76 
 
compared to the first tertile. No factors were associated with fracture in patients with 
T2D.  
 
 
 
Figure 17. Fracture risk by sclerostin levels in patients with type 1 diabetes. * 
Statistical significantly different from the reference. Adjusted by age, BMI, gender, 
diabetes duration, previous major osteoporotic fracture, Hip T-score, and 25 OHD 
vitamin level. 
  
5.7 PAPER 7: “THE EFFECT OF GLUCOSE ON BONE – DIRECT 
OR INDIRECT?” 
As the differences in turnover markers in diabetes were not spurious brought about 
by assay problems and as turnover was associated more to actual glucose levels than 
to HbA1C, a methodological study was performed to further investigate if it was the 
glucose load per se or the mode of ingestion (oral or i.v.) that affected turnover. An 
effect of oral ingestion and not i.v. infusion would perhaps point at an effect of 
factors from the gut. 
Table 9 presents characteristics of the healthy men. On average they were 30.6 years 
old and normal weight. None had bone metabolic disease or diabetes based on 
fasting p-glucose, HbA1c or two hour OGTT values.  
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Variables Mean Range 
Age (years) 30.6 25–49 
Alcohol (units pr. week) 9.6 0.5-20 
BMI (kg/m
2
) 24.2 21.0-28.8 
HbA1c 33.2 29-39 
Mean glucose 5.6 5.0-6.5 
PTH 4.4 3.0-6.9 
Vitamin D 59.2 42-75 
Calcium 1.24 1.17-1.28 
s-CTX 0.63 0.23-0.93 
s-P1NP 73.5 31.8-138.5 
Table 9 Characteristics of the included subjects (n=12). 
 
Figure 18 presents data on p-glucose levels by time and intervention. The p-glucose 
levels made a rapid increase and reached its maximum after 35 minutes with a 
secondary peak around 90 minutes. The p-glucose levels dropped and reached 
starting values after 150 minutes and made an additional drop for the remaining 30 
minutes.  The OGTT and IIGI glucose values did not differ at any time point and are 
thus comparable.   
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Figure 18. Glucose levels by time and intervention. 
 
The repeated measurements ANOVA revealed a significant decrease in s-CTX over 
time and a significant interaction between time and intervention (OGTT or IIGI). S-
P1NP did not change by time or intervention as illustrated by Figure 19.  
 
 
Figure 19. P1NP levels by time and intervention. 
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At the start of both interventions s-CTX was similar of 0.63 µg/l. Figure 20 presents 
s-CTX levels by time and intervention. S-CTX levels were significantly decreased at 
both interventions after one hour and the nadir of decrease was after two hours for 
the OGTT and after three hours for the IIGI. At all time points s-CTX decreased 
significantly more at the OGTT than the IIGI. 
 
 
Figure 20. CTX levels by time and intervention. 
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6. DISCUSSION 
6.1 SUMMARY OF RESULTS 
 Bone turnover markers were altered in patients with diabetes with lower s-
OC and s-CTX levels compared to controls. S-BAP, s-PTH, and s-calcium 
were not different between diabetes and non-diabetes subjects. The 
differences may be due to alterations in sclerostin and OPG. (Paper 1,2, and 
3).  
 Patients with T1D had increased p-P1NP, p-OC, and s-RANKL whereas s-
OPG was lower compared to patients with T2D. P-sclerostin and p-FGF-23 
were not different between patients with T1D and T2D. (Paper 5). 
 Thus, bone turnover markers are different in patients with diabetes 
compared to non-diabetes subjects, but also differently between patients 
with T1D and T2D. (Paper 1, 2, 3, and 5). 
 Acute changes of bone turnover may appear after a glucose load either 
given intravenously or orally. Thus, s- CTX decreased significantly after 
ingestion and infusion of glucose and also more with the OGTT than the 
IIGI. However, s-P1NP was not different between OGTT and IIGI and did 
not change significantly over time. (Paper 7). 
 The effect of glucose added to serum samples did not change bone marker 
levels and thus the effect of glucose on bone turnover markers is not due 
not due to an immunochemical masking effect by bone marker glycation. 
(Paper 2). 
 In patients with T1D and T2D p-glucose was positively associated with s-
OPG levels and in patients with T1D inversely associated with markers of 
bone formation and resorption. HbA1c was only significantly associated 
with p-OC. (Paper 5) 
 Hip T-score and tibia tissue stiffness was significantly higher in patients 
with T2D than patients with T1D, whereas differences in spine and femur 
T-score were abolished in the adjusted models. 
 Possible fracture predictors were examined and LDL-cholesterol levels 
were associated with risk of fracture in patients with T2D with lower risk at 
higher levels. HbA1c was not associated with the risk of fracture. (Paper 4). 
 P-sclerostin was, independently of hip T-score, associated with the risk of 
fracture in patients with T1D with lower risk at higher levels. (Paper 6). 
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6.2 BIOCHEMICAL BONE TURNOVER MARKERS 
6.21 DIFFERENCES IN BONE TURNOVER MARKERS BETWEEN TYPE 1 
AND TYPE 2 DIABETES 
We hypothesized that patients with T1D have higher bone turnover measured by 
bone turnover markers compared to patients with T2D. The hypothesis was based on 
previous results of low BMD in patients with T1D, increased BMD in patients with 
T2D (11), and that bone loss relates to bone turnover (95). In paper 5 we found 
increased bone formative markers (p-OC and p-P1NP) in patients with T1D 
compared to patients with T2D, whereas p-CTX was not statistically significant but 
with a trend towards increased levels in patients with T1D. Unbound s-RANKL 
levels were increased in patients with T1D compared to patients with T2D, which 
may be explained by a higher level of s-OPG in patients with T2D. This difference 
in free active s-RANKL may explain the differences in p-OC, p-P1NP, and p-CTX 
as RANKL by binding to RANK promotes bone resorption that is tightly coupled to 
bone formation (25). S-RANKL has been reported not to differ between patients 
with T1D and T2D (28-30), which is in contrast to our results. However, two of the 
three studies reporting s-RANKL values measure it in the OPG bound form (28, 29) 
while the third does not provide information on whether s-RANKL is measured 
OPG bound or unbound (30). Neither p-FGF-23 nor p-sclerostin differed between 
patients with T1D and T2D. P-25 OH vitamin D was higher in patients with T1D; 
however for both patients with T1D and T2D the means were within normal range 
and thus should not affect our results. In the meta-analysis s-25 OH vitamin D was 
decreased and s-PTH unchanged in patients with diabetes compared to controls 
(114), this may be due to a blunted PTH response which previously has been 
observed in patients with insulin treated diabetes exposed to hypocalcemia (174).  
Other studies have assessed bone turnover marker differences between patients with 
T1D and T2D, however these studies were smaller with group sizes from 21 to 73 
(37, 91, 91, 175, 176). These studies report no difference in bone turnover markers 
between patients with T1D and T2D. S-sclerostin was reported lower in patients 
with T2D compared to patients with T1D, which may be explained by an age 
difference of twenty years (37). We found evidence of increased bone formation and 
also a possible increased bone resorption in patients with T1D compared to patients 
with T2D. This difference may be driven by the RANKL/OPG system. 
 
6.22 DIFFERENCES IN BONE TURNOVER MARKERS BETWEEN 
PATIENTS WITH DIABETES AND NON-DIABETS SUBJECTS 
We hypothesized that bone turnover was different between patients with diabetes 
and controls. This was examined in the meta-analysis (114).  Levels of s-OC, s-
CTX, and s-25 OH vitamin D were lower in patients with diabetes, whereas u-NTX 
was borderline increased. Bone markers were very heterogeneous between studies; 
however the differences are reliable due to the comparison being made within each 
study. A lower bone turnover measured by s-CTX and s-OC is supported by the 
systematic review although studies also report no difference between subjects with 
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and without diabetes (116). Although the differences were evaluated quantitatively, 
the studies displayed heterogeneity. Factors as age, diabetes type, and diabetes 
duration may affect the results and explain the heterogeneity and should be further 
investigated.  
The difference between the direction of s-CTX and u-NTX gives a complex picture 
of bone turnover in patients with diabetes. It is an odd finding as a review stated that 
no difference is present between CTX and NTX independent of measurement in 
serum or urine (125). The review (115) also concluded that bone turnover may be 
dissociated in diabetes where only selected markers decrease (s-CTX, s-TRAP and 
s-OC) and others do not. However, the results are restricted as the data are provided 
from several heterogeneous populations and thus diversity in patient characteristics 
may explain the difference. 
In paper 5 the reported levels of p-FGF-23, p-sclerostin, s-RANKL, and s-OPG were 
different from previously reported intervals. P-FGF-23 was above the normal range 
(19.1 – 93.2 RU/ml) proposed from the analysis of 170 healthy individuals (170). 
Furthermore, the c-terminal FGF-23 (analyzed in paper 5) was stable during the day 
and not affected by food intake or physical activity (170). Thus, patients with 
diabetes seem to have increased p-FGF-23 levels. This may be due to increased s-
phosphate levels, which were found in the meta-analysis (114). P-sclerostin levels 
for patients with T1D and T2D reported in paper 5 were increased compared to 
previous population based values in men and women (177). This is in line with the 
results of paper 1 were s-sclerostin levels seemed increased in patients with T2D 
compared to controls. Increased sclerostin levels will result in an inhibition of the 
Wnt pathway and a decreased bone formation, which may explain a decrease in 
bone strength in these individuals. Compared to the manufactures reference range s-
RANKL levels were increased. This is supported by the internal healthy control, 
which was close to the mean of the manufacturer’s range (from the Department of 
Clinical Biochemistry, Aalborg University Hospital). S-OPG levels matched the 
manufacturer’s reference range. Thus, p-sclerostin and s-RANKL seemed to be 
altered in patients with diabetes compared to non-diabetes subjects. Theoretically an 
increased p-sclerostin and decreased s-RANKL would decrease both bone resorption 
and formation, which is in line with the decreased s-OC and s-CTX in patients with 
diabetes observed in the meta-analysis (114). As described in section 1.6 the 
evidence from bone biopsies was conflicting and limited and gives no clear 
indication of whether diabetes may have decreased bone turnover (95, 110, 111). 
CTX, P1NP, and OC reflect the bone turnover. Compared to the proposed reference 
ranges the levels of p-CTX, p-P1NP, and p-OC observed in paper 5 was not 
different. However, when comparing the results to a population of similar age both 
p-OC and p-CTX seem to be lower in patients with diabetes (178, 179). 
 
6.23 BONE TURNOVER MARKERS AND FRACTURE 
In non-diabetes subjects bone turnover markers predicted fragility fractures and 
related to deterioration of bone (180) and thus bone turnover may be a marker of 
fracture. In patients with diabetes s-PTH, s-BAP, s-OC, u-NTX, and s-CTX did not 
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predict fractures (82, 128, 153, 167, 181-183). However, the combination of low s-
P1NP and high s-CTX was associated fracture in patients with diabetes (130) and 
increased s-sclerostin in patients with T2D was associated with fractures (127, 129).  
In the clinical study p-sclerostin levels had same direction as proposed above in 
patients with T2D, however results were not significant. In patients with T1D the 
upper tertile of p-sclerostin was associated with an 81 % decreased fracture risk 
compared to the lowest tertile independent of BMD. The role of sclerostin may thus 
be very different between patients with T1D and T2D. In patients with T1D a 
decrease in bone formation may be beneficial, whereas it may be harmful in patients 
with T2D. This may be explained by the bone formation which is higher in patients 
with T1D. Longer follow up time is needed to examine the effects on hip fracture, 
which may be the main fracture preventive goal in diabetes. Another possible 
fracture predictor may be IGF-1 as described in section 1.7. An abstract presented at 
the European Association for the Study of Diabetes (EASD) 2014 in Vienna 
reported that IGF-1 was associated with incident fractures in postmenopausal 
patients with T2D (131). IGF-1 and sclerostin are therefore potential fracture 
predictors in patients with diabetes.  
The large heterogeneity of bone turnover markers in the meta-analysis limit the use 
of standard bone turnover markers (CTX, P1NP, OC, BAP) as fracture predictors in 
patients with diabetes, as they relate to patient characteristics (age, sex, diabetes 
duration) and method used to analyze the marker (114). Furthermore, the p-glucose 
level at measurement may affect the result. To help the interpretation of bone 
turnover markers and an effort to standardize the measurement in diabetes; 
measurements should always be accompanied with a p-glucose and a thorough 
description of the patients with diabetes (age, sex, diabetes duration, smokers, 
medication use, diabetes related complications, p-creatinine).  
 
6.3 GLUCOSE AND BONE TURNOVER 
It was hypothesized that glucose decreases bone turnover markers. Glucose may 
thus explain the large heterogeneity of bone turnover markers between studies by the 
lack of a normal fasting state in patients with diabetes (47). This is also present in 
the study by Gennari et al., that reported decreased fasting s-CTX in patients with 
T1D and T2D compared to controls; however both patients with T1D and T2D have 
elevated fasting p-glucose (7.3 mmol/l and 7.8 mmol/l, respectively). To determine 
whether a possible relationship is due to immunochemical masking effect by bone 
marker glycation of bone turnover markers we examined the effect of in vitro added 
glucose to serum. The addition of glucose to serum did not change bone turnover 
markers, thus glucose does not interact with the analysis of the bone turnover 
markers. In the clinical study we found evidence of an association between bone 
turnover markers and p-glucose in patients with diabetes; p-CTX, p-P1NP, and p-
OC, were negatively associated with and s-OPG positively associated with p-
glucose levels in patients with T1D in the clinical study. S-OPG was associated with 
p-glucose in patients with T2D and p-CTX, p-P1NP, and p-OC trended towards 
lower values with increased p-glucose levels. Furthermore, ingestion of glucose 
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orally or intravenously decreases s-CTX levels in healthy men. However, the 
decrease was most pronounced in the OGTT. S-P1NP levels were unaffected of the 
way of administration of glucose. Although, glucose may affect bone turnover the 
BMD values reported in paper 6 were not associated with long term HbA1c values 
and thus density does not seem to relate to glycemic control. 
In diabetes the effect of glucose on bone turnover markers may be through a direct 
stimulation of the OPG production in osteoblasts. Cunha et al. showed that 24 hours 
of hyperglycemia increased OPG 15 times more than RANKL in osteoblast-like 
cells (144); however Garcia-Hernandez et al. found the opposite after 7 and 14 days 
(143). Other studies reported decreased s-OPG after glucose infusion: OGTT did not 
change s-OPG levels in postmenopausal women with T2D after 2 hours, however s-
OPG was decreased in non-diabetes individuals (140) and p-OPG decreased after 4 
hours of hyperglycemic clamp in healthy individuals and p-OPG was negatively 
associated with serum insulin (184). The findings of Chailurkut et al. support an 
alteration of s-OPG under hyperglycemia in patients with diabetes as hyperglycemia 
lowered s-OPG in healthy individuals, but not in patients with T2D (140). Our 
finding of an association between p-glucose and s-OPG in patients with diabetes 
may be both due to prolonged or acute hyperglycemia. The association between s-
OPG and p-glucose may also be due to very low serum insulin levels, which is very 
likely to be present in hyperglycemic patients with T1D and the relatively low 
insulin levels in relation to hyperglycemia in patients with T2D.    
As described in the introduction; OGTT decreased s-CTX, s-P1NP, and s-OC in 
healthy individuals (137). This effect may be due to glucose itself or factors released 
during gastro-intestinal absorption. Somatostatin abolished the effect of an OGTT 
and injection with GLP-2 decrease s-CTX which both suggest an indirect effect of 
glucose through gastro-intestinal hormones (137, 138). We observed a decrease in s-
CTX at both OGTT and IIGI whereas p-glucose levels did not differ. However, s-
CTX decreased significantly more at the OGTT. These results suggest that the effect 
of glucose is mediated by the gastro-intestinal hormones, but it may mediate via a 
promotion of glucose itself as the IIGI also decreased s-CTX. The decrease of s-
CTX may also be through insulin as the insulin response is amplified by the 
incretins. In vitro insulin added to the hyperglycemic condition partially prevented 
the OPG response (144). Chailurkit et al. observed a smaller decrease in s-CTX at 
an OGTT in patients with T2D compared to normal glycemic individuals after two 
hours (140). This may be due to an impaired insulin or gastro-intestinal response or 
due to slower uptake of glucose in patients with T2D. A study support the 
association of p-glucose and bone turnover markers in young patients with T1D; s-
OC, s-CTX, and s-TRAP were lower at the diabetes onset but normalized after three 
months, but also with a corresponding drop in HbA1c from 11.3 to 5.9 % (185) . 
The differential association between p-glucose and bone turnover markers may be 
due to the higher level of bone turnover markers in patients with T1D, which may be 
more susceptible to increased p-glucose levels than patients with T2D.   
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6.4 BONE STRUCTURE IN DIABETES 
It was hypothesized that patients with T1D and T2D differ in bone density measured 
by BMD, where BMD is decreased in patients with T1D. In paper 6 DXA T-score, 
reflecting BMD, was lower in patients with T1D at the hip, femur, and spine 
compared to patients with T2D. Only hip T-score remained significantly different in 
the multiple adjusted analyses. Hip BMD may thus explain some of the difference in 
hip fractures reported. Our measures of BMD in patients with T1D and T2D are 
comparable to the reported Z-scores reported by Vestergaard (11). Conversion of 
the T-score to the age and gender matched Z-score revealed a value of -0.28 and 
+0.48 by in patients with T1D and T2D, respectively. Vestergaard reported similar 
values of -0.37 and +0.22 for patients with T1D and T2D, respectively and 
concluded that it could not explain the increased fracture risk (11). In paper 6 the T-
score of hip, femur, and spine were not predictive of fracture in the adjusted 
analyses. Although we are not able to demonstrate a relation between BMD and hip 
fracture it adds to the evidence of relatively high BMD levels compared to the 
increased fracture risk in patients with diabetes. 
Neither density, structural parameters nor failure load measured by HRpQCT were 
different between patients with T1D and T2D. As described in the introduction a 
study found deficits in trabecular and cortical microarchitecture in patients with T1D 
and microvascular disease compared with patients with T1D without microvascular 
disease (103). No association was present between microvascular disease and 
trabecular or cortical microarchitecture in paper 5 in neither patients with T1D nor 
T2D. The differences between the studies may be due to a lower number of patients 
or lower age among patients with T1D (mean age 46 years) in the study by 
Shanbhogue et al. (103). Low power may increase the risk of a type 1 error whereas 
age differences reflect differences in patient characteristics between T1D and T2D. 
However, age per se may also affect bone composition and biomechanical 
properties. Bone tissue stiffness at the tibia was lower in patients with T1D also in 
the adjusted analysis. Cortical pore diameter and the standard deviation of cortical 
pore diameter were higher in patients with T1D at both the radius and tibia 
compared to patients with T2D. None of the porosity parameters differed in the 
adjusted analyses. Thus, cortical microstructure, density, and structure were affected 
in the same manner in patients with T1D and T2D. Measures of cortical porosity 
have discriminated fracture in patients with T2D (100) and if it predicts fracture it is 
likely to do so in both diabetes types. Bone tissue stiffness is a measurement of bone 
mechanical competence and not solely a bone density parameter as the hip T-score. 
The peripheral bone tissue stiffness strongly correlated with the central tissue 
stiffness at the lumbar spine and femur (186). Tissue stiffness has proved as a 
fracture predictor in non-diabetes subjects (187, 188) and may also do this in 
patients with diabetes. Thus, the tissue stiffness may be able to elucidate the 
discrepant fracture rates in patients with T1D and T2D.  No deficiency in bone 
mineral accumulation is present in the patients with diabetes based on the T-score, 
however as bone is composed of mineral and matrix in a tight structure any 
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deficiency may affect bone mechanical competence and we were not able to 
determine the collagen structure or matrix by the structural bone scans.  
 
6.5 FRACTURE PREDICTORS IN DIABETES 
It was hypothesized that HbA1c levels predict fractures in patients with diabetes. In 
paper 4 no association between HbA1c and fracture in patients with diabetes was 
present. Neither falls nor hypoglycemic events were associated with fracture risk in 
neither paper 4 or 6. Instead LDL-cholesterol was associated with fractures for both 
the whole cohort of patients with diabetes as well as limited to patients with T2D in 
paper 4. None of the antidiabetics was associated with fracture risk. To avoid the 
effects of renal disease nephropathy cases were excluded. LDL-cholesterol levels of 
0-1.5 mmol/L were associated with increased risk of fracture whereas levels of more 
than 2.4 mmol/l was beneficial in terms of fracture risk compared to the reference 
level of 2.2-2.4 mmol/l. Current ADA guidelines recommend LDL-cholesterol < 1.8 
mmol/l for subjects with prior cardiovascular disease and < 2.5 mmol/l for others 
(189). Although LDL-cholesterol lowering was beneficial a review concluded that 
the optimal target value was not firmly established and further research is needed 
(190). The results of paper 4 indicate that the optimal level might not be as low as 
possible with respect to fracture risk. LDL-cholesterol may affect bone turnover; in 
vitro LDL-depletion of osteoclasts-like cells inhibited the TRAP production which 
was abrogated with the addition of LDL (191). Also LDL prolonged the survival of 
osteoclast-like cells, whereas HDL induced apoptosis (192). Oxidized LDL may 
stimulate an osteoclast-associated receptor, which is a co-stimulator of osteoclast 
differentiation (193). Thus osteoclasts function may depend on LDL. Osteoblasts are 
found to have a LDL-receptor (194) and LDL in native and oxidized form killed 
osteoblasts like cells, although the level was not determined (195). LDL may also 
associate with the LRP-5 and 6 receptors, which are positive regulators of the Wnt 
pathway and stimulate osteoblast differentiation and bone formation (196, 197). In 
paper 5 an association between bone formation markers and LDL-cholesterol was 
observed which may suggest that LDL-cholesterol possibly through LRP-5 and 
LRP-6 may influence bone turnover. Loss of function mutations of the LRP-5 gene 
presents with osteoporosis, diabetes, impaired glucose tolerance, and altered lipid 
metabolism (198). LDL may stimulate the Wnt pathway and increase bone 
formation, but at possibly supra-physiological levels LDL may kill osteoblasts. 
Animal models are needed to translate the in vitro evidence of LDL and bone. 
Statins have been proposed to decrease fracture risk by HMG CoA-reductase 
activity (199). The association of LDL-cholesterol with fracture was independent of 
statins and statins itself did not associate with fractures. The JUPITER trial, a 
randomized controlled trial, report no beneficial effect of statins and even present a 
trend of more fractures in the treated group (200). Thus, statins may be a double 
edged sword in relation to bone with a beneficial effect through the mevalonate 
pathway (199) and a negative through LDL-cholesterol and Wnt (196).    
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6.6 VERTEBRAL FRACTURE 
The previous meta-analyses especially reported an increased risk of hip fracture in 
patients with diabetes, whereas vertebral fractures (11, 48)  were not increased. In 
the clinical trial 11.6 % of the patients with diabetes were diagnosed with a vertebral 
fracture and when limiting it to the patients examined by X-ray 28 % of the patients 
were diagnosed with a vertebral fracture. Most of these were Genant classification 1 
and thus only likely to be diagnosed by the spine X-ray examination and not by a 
clinical diagnosis. In comparison to vertebral fractures, hip fractures are rarely 
undetected. The risk of vertebral fractures may thus also be increased in patients 
with diabetes, but due to rare use of the spinal X-ray examination it may not be 
diagnosed and registered as often as hip fractures. Furthermore it may be important 
to determine the vertebral fractures by spinal X-ray and not VFA as they detected 
vertebral fracture in 28 % and 2 %, respectively. The discrepancies between spinal 
X-ray and VFA may be due to a large amount of mild fractures in the x-ray 
evaluated population (80 % of the fractures); however it may be a major problem as 
fracture predictors are sparse in patients with diabetes and a mild vertebral fracture 
may be the first sign of ongoing diabetic bone disease.  
 
6.7 THE DIABETIC BONE 
In diabetes the paradox of increased fracture risk and apparent normal bone mineral 
remains unsolved. BAP is a marker of the mineralization process and while other 
turnover markers were decreased in diabetes s-BAP remained normal (110, 114, 
116, 201, 202). Thus mineralization may continue at normal rate, whereas collagen 
and matrix remodeling is suppressed. This may lead to hypermineralized fragile 
bone as in some osteopetrotic subjects (116). It is also supported by bone biopsies 
from the study of Manavalan et al. (110); the biopsies from patients with T2D 
present reduced bone formation rate and mineralizing surface, however the adjusted 
apposition rate was not lower in patients with T2D reflecting that the decreased 
mineralizing surface is due to a decreased bone turnover. The hypermineralization 
may be caused by increased glucose levels (Figure 6) (143) although evidence is 
conflicting (144). Cunha et al. (144) found indices of decreased mineralization 
during 24 hours of hyperglycemia, whereas the hypermineralization observed by 
Garcia-Hernandez et al. was for 7 and 14 day periods (143). The discrepancy 
between the in vitro studies may simply be due to the differences in time intervals so 
a short period of hyperglycemia decrease bone mineralization, whereas a longer 
period as in patients with diabetes increase bone mineralization and hypermineralize 
bone. In spite of the hypermineralization observed BAP levels decreased at the 
highest level of glucose (24 mmol/l) (143), however these levels are supra-
physiological for a longer period even in patients with diabetes. In a model using 
T1D mice osteoblasts, both hyperglycemia and hyperosmolality increased 
peroxisome proliferator-activated receptor γ (PPAR-γ) (203). Glitazones function 
through the PPAR- γ pathway by increasing insulin sensitivity, but also increase 
bone resorption and lead to preferential differentiation of mesenchymal stem cells 
into adipocytes instead of osteoblasts (135, 204). Also, based on cell cultures 
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hyperglycemia has been suggested to divide osteoblastic precursor cells into an 
adipogenic pathway causing inflammation in the bone (205). Thus, long term 
hyperglycemia may have detrimental effects to the bone by activating the PPAR- γ 
pathway. The meta-regression revealed that increasing HbA1c levels in patients with 
diabetes was a positive determinant of s-BAP (114). The associations between p-
glucose and bone turnover markers in diabetes individuals suggest that patients with 
diabetes are in a state of constant cycling of decreasing and increasing bone turnover 
due to fluctuations in p-glucose. The association may be through an up regulation of 
OPG expression in either osteocytes or osteoblasts with the latter most likely. 
Furthermore, the effects of insulin and GLP-2 are unclear as they may be mediators 
of p-glucose or promoters of the response. Another factor causing 
hypermineralization in patients with diabetes may be a blunted PTH response, which 
previously have been reported and is supported by the findings of the meta-analysis 
(114, 174). Patients with hypoparathyroidism, which are characterized by a lack of 
PTH or a lacking function of PTH have very high BMD levels (206). Other factors 
than glucose, may thus cause hypermineralization in patients with diabetes. Figure 
21 presents the hypermineralization hypothesis.  
 
 
Figure 21. The hyperminerilazation hypothesis. 
 
In the hypermineralization hypothesis the osteoblast is central. In patients with 
diabetes, the osteoblast may not produce sufficient amounts of collagen to balance 
the increased bone resorption in diabetes patients as reflected by decreased s-CTX 
and s-OC levels (114), however s-BAP and the mineralization process is unaffected 
(116). This imbalance between collagen production and mineralization may turn the 
bone fragile with a decreased calcium phosphate ratio of the mineral; resulting in 
low quality mineral (143). In an attempt to alter this ratio the bone react with a 
blunted PTH response and an increase in FGF-23, thus trying to maintain the 
calcium in the bone and remove phosphate, however this may have adverse effects 
and further hypermineralize the bone as in hypophosphatemic rachitis (207). 
Furthermore, the hyperglycemic conditions may increase the production of OPG by 
the osteoblast and thereby inhibit the osteoclast and the bone resorption. This 
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inhibition of the osteoclast and a blunted PTH response with lesser osteoclast 
activity causes the mineral accumulate in the bone as it is not removed in the normal 
rhythm. The hypermineralization may be regulated by fluctuations in p-glucose or 
accompanied effects of the gastro-intestinal hormones (as GLP-2), where 
hyperglycemia decrease bone turnover while mineralization is unaffected. The 
fragility of the hypermineralized bone may be further enhanced if the activity 
Wnt/LRP-5 pathway is reduced by low LDL-cholesterol levels. 
 
6.8 EXPLANATIONS OF FRACTURE IN PATIENTS WITH 
DIABETES 
Figure 22 depicts the factors that may influence the increased fracture risk in 
diabetes patients and to adds to Figure 8 in section 1.9. The association between 
diabetes and fracture is not fully explained by BMD, FRAX, diabetes complications 
or falls. However, each factor may contribute to it. As described above, 
hyperglycemia may decrease bone formation and hypermineralize the bone, which 
leave the bone weaker than what bone density explains. The bone fragility may be 
enhanced by a lack of LDL-cholesterol, which may activate bone formation by the 
Wnt pathway. Sclerostin which is antagonist of the Wnt pathway may display 
different actions in patients with T1D and T2D as increasing levels decrease fracture 
risk in patients with T1D and increase fracture risk in patients with T2D. This 
difference may be due to the lower bone formation overt in patients with T2D 
compared to patients with T1D, which also may be reflected by the BMD 
differences. Thus, a high p-sclerostin level in patients with T2D may with harmful 
effect further decrease the bone formation, whereas a decrease in bone turnover may 
be beneficial in T1D patients, which theoretically may be caused by a lower 
accumulation of weak collagen cross-links. Furthermore, bone tissue stiffness may 
contribute to the fracture risk difference between T1D and T2D as it differed 
between the patient groups. Several factors may contribute to the bone fragility 
observed in diabetes patients and so far no one factor has been able to explain the 
fracture risk fully.   
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Figure 22. Factors that may influence the risk of fracture in diabetes patients. LDL: 
LDL-cholesterol, OPG: Osteoprotegerin, AGE: Advanced Glycation End, TBS: 
Trabecular bone score, BMD: Bone mineral density, FRAX: Fracture Risk 
Assessment Tool. Blue arrows indicate relationships. Red arrows indicate 
inhibitory effects. Green arrows indicate a positive effect or secretion. X mark 
associations that do not explain the increased fracture risk in diabetes patients. ↓ 
marks a decrease compared to subjects without diabetes. ↑ marks an increase 
compared to subjects without diabetes. ? marks if a relationship is unknown. 
  
6.9 GENERALISABILITY  
The results presented in this thesis from paper 1-6 are generalisable to patients with 
diabetes. The association of LDL-cholesterol and fracture was only estimated 
specifically in patients with T2D, whereas the cross-sectional results is provided 
from a relatively dysregulated diabetes population. As the meta-analysis does not 
discriminate on patient characteristics; the results may apply to all patients with 
diabetes. The paper 7 is a basic physiological study, but the results are not 
generalisable to patients with diabetes, only healthy young men.  
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7. CONCLUSION 
The initial hypotheses were: 
Primary hypotheses: 
I. Patients with type 1 and type 2 diabetes differ in bone density 
measured by BMD, where BMD is decreased in type 1 diabetes. 
II. To explain the expected decreased in BMD in patients with type 1 
diabetes they have higher bone turnover measured by circulating 
biochemical markers compared to patients with type 2 diabetes. 
Secondary hypotheses 
III. Bone turnover markers are decreased in patients with diabetes 
compared to non-diabetes controls. 
IV. HbA1c levels predict fractures in patients with diabetes. 
V. Increasing plasma glucose decreases circulating bone turnover 
markers. 
 
Conclusions on initial hypothesis are: 
I. Patients with type 1 diabetes had lower BMD at the hip compared to 
patients with type 2 diabetes independent of the patient characteristics. 
II. Patients with type 1 diabetes had higher bone formation markers 
compared to patients with type 2 diabetes. 
III. Patients with diabetes had decreased markers of resorption and 
formation compared to non-diabetes controls. 
IV. HbA1c did not predict fractures in patients with diabetes; however 
LDL-cholesterol and p-sclerostin may be useful markers. 
V. P-glucose was associated with lower bone turnover markers in patients 
with diabetes, which may be caused by increased s-OPG. In healthy 
males both oral and intravenously administered glucose decrease bone 
resorption, but not formation. 
 
In conclusion, we observed indices of lower bone turnover and increased bone 
density and tissue stiffness in patients with T2D compared to patients with T1D. The 
bone turnover in patients with diabetes seemed to be lower than in non-diabetes 
controls. P-glucose levels were associated with increased s-OPG and decreased bone 
turnover, thus the diabetic bone disease may be due to p-glucose fluctuations 
altering the normal bone remodeling. Our results point at possible beneficial effects 
of glycemic control on bone health in patients with diabetes. Furthermore, we found 
indices of the usage of p-sclerostin and LDL-cholesterol as fracture predictors in 
patients with diabetes. 
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8. PERSPECTIVE  
The presented study provides valuable information on bone status in patients with 
diabetes. Clinicians should be aware of the association between diabetes and 
osteoporosis, which is not reflected by the BMD. If osteoporosis is suspected, the 
DXA scan may be accompanied with an x-ray of the spine, as vertebral fractures are 
prevalent in patients with diabetes.  
Diabetic bone disease may be caused by the insulin deficiency in patients with T1D 
and the relative insulin  deficiency compared to glycemia in patients with T2D 
causing a hyperglycemic state, which decrease bone turnover, but also cause 
hypermineralization. Thus, diabetic bone disease may be prevented by strict 
glycemic control. Future investigations should apply the advanced techniques of 
continuous glucose monitoring to map the circadian rhythm of both p-glucose and 
bone turnover in patients with diabetes, which may be very different from what is 
seen in non-diabetes subjects. Furthermore, more evidence is needed on the effect of 
glucose on osteoblasts, osteoclasts, and osteocytes and if the hypermineralization 
caused by hyperglycemia may be translated into animal models.  
Evidence of different bone structure between patients with T1D and T2D was found. 
The difference in hip BMD, may explain some of the discrepancy in fracture rates 
between patients with T1D and T2D, but still does not explain the increase 
compared to non-diabetes subjects. Tissue stiffness evaluated with the HRpQCT, 
which use very low x-ray doses, may further explain the differences in fracture as it 
is not only a bone density parameter. Future investigations should evaluate the 
association between HRpQCT parameters and fracture. Furthermore, a comparison 
between bone quality estimated by bone tissue biopsies and structural parameters is 
needed to determine if tissue stiffness or porosity may be a marker of decreased 
bone biochemical competence.  
Finally we found associations between p-sclerostin levels and fracture in patients 
with T1D and LDL-cholesterol levels and fracture in patients with T2D. These 
results should be used for hypothesis generation and should be confirmed by other 
observational studies.  
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Diabetes mellitus is associated with an increased risk of fracture with and 
current fracture predictors underestimate fracture risk in both type 1 and type 
2 diabetes. Thus, further understanding of the underlying causes of diabetic 
bone disease may lead to better fracture predictors and preventive measures 
in patients with diabetes.
This PhD thesis reports the results of two systematic reviews and a me-
ta-analysis, a state-of-the-art intervention study,  a clinical cross-sectional 
study and a registry-based study  all examining the relationship between di-
abetes, glucose, and bone.
Patients with type 2 diabetes had lower bone turnover markers compared to 
patients with type 1 diabetes and bone mineral density and tissue stiffness 
were increased in patients with type 2 diabetes. The bone turnover markers 
were inversely associated with blood glucose in patients with diabetes and 
both an oral glucose tolerance test and an intravenous test decreased bone 
resorption markers in healthy men. In the registry based study; fracture risk 
in patients with type 2 diabetes were associated with low LDL-cholesterol 
levels.
 
In patients with diabetes, bone turnover and bone strength are associated with 
clinically relevant measures such as cholesterols and fluctuate on the basis 
of blood glucose level alterations.
